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The cellular degradation system actively participates in cell homeostasis. Despite ongoing 
efforts and much progress in recent years, the underlying mechanisms of these pathways are 
not entirely understood. This thesis aims to contribute further insights how microRNAs and 
viral oncoproteins regulate key genes involved in cellular degradation pathways. 
In Paper I, we found overexpression of miR-223-3p in testicular germ cell tumors (TGCTs), 
in which its expression was negatively correlated with the mRNA level of the FBXW7 
ubiquitin E3 ligase. Overexpression of miR-223-3p suppressed, while its inhibition increased, 
FBXW7 protein level in TGCT cell lines, suggesting FBXW7 as a target of miR-223-3p. 
Using both gain- and loss-of-function experiments, we showed that miR-223-3p induced cell 
growth and reduced apoptosis. Ectopic expression of the FBXW7 open reading frame could 
reverse the effect of miR-223-3p. In conclusion, we suggest the oncogenic role of miR-223-3p 
– FBXW7 regulation in TGCT. 
In Paper II, we demonstrated that miR-375, miR-30a-3p and miR-30a-5p are regulated by 
Merkel cell polyomavirus (MCPyV) T-antigens through the DnaJ domain. These miRNAs 
could suppress autophagy and target ATG7, SQSTM1 (p62) and BECN1. Lower protein 
levels of ATG7 and p62 are associated with MCPyV-positive MCC tumors. Additionally, we 
showed that ectopic expression of MCPyV oncoproteins could suppress autophagy and 
blockage of autophagy rescued Torin-1 mediated cytotoxicity in MCC cells. This study 
provides evidence that MCPyV oncoproteins induce microRNAs and suppress autophagy in 
MCC, suggesting the importance of autophagy suppression in protecting MCC cell survival. 
In Paper III, we uncover a function and mechanism of MCPyV oncoprotein in autophagy 
evasion through c-KIT receptor tyrosine kinase. We show that the viral oncoprotein promotes 
c-KIT retention in late endosomes through its Vam6p binding site, which promotes c-KIT 
binding to Beclin-1 and enhances Beclin-1-BCL2 interaction. Silencing of c-KIT induces 
autophagy, which leads to degradation of the viral oncoprotein. Thus, MCPyV has developed 
a strategy to hijack cellular degradation system to sustain the viral oncoprotein expression. 
In Paper IV, we identify CK20 paranuclear dot as a part of aggressome in MCC, in which 
these structures are associated with MCPyV status, localized at microtubule-organizing center 
and dependent on BAG3 expression and dynein-mediated microtubule transport. 
Additionally, we show that the MCPyV truncated large T-antigen promotes aggresome 
formation through its Vam6p binding site. This study suggests a model of BAG3-dependent 
aggresome formation contributed by viral oncoprotein in MCC. 
Overall, this thesis work has demonstrated the involvement of microRNAs and viral 
oncoproteins in regulation of cellular degradation pathways, which contributes to the 
understanding of the molecular interplays between cellular degradation system and cancer 
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The cellular degradation system is one of the essential biological processes to keep cellular 
homeostasis. It acts as a catabolic mechanism to interplay with multiple cellular processes, 
including but not limited to energy balance, macromolecule clearance and recycling, 
modification of regulatory proteins and expression control, and immunity against pathogen 
invasions. Therefore, the cellular degradation system is highly important in various 
pathophysiology processes, especially in cancer. This thesis partly contributes to the 
understanding of how cellular degradation pathways are regulated by microRNAs and viral 
oncoproteins. 
 
1.1 EUKARYOTIC PROTEIN DEGRADATION SYSTEMS 
In order to maintain normal intracellular homeostasis, eukaryotic cells require the cellular 
degradation system to break down and recycle cellular proteins for quality control. Two 
pathways have been extensively studied, i.e. the lysosome-mediated and the ubiquitin-
proteasome degradation systems. Dysfunction of these two systems could contribute to 
pathological situations, such as neurodegenerative diseases and carcinogenesis. 
 
1.1.1 Lysosome-mediated protein degradation 
The lysosome is a single-layer round-membrane cytoplasmic vesicle mainly containing acid 
hydrolases that are active in acidic pH environment (De Duve, 1963).  It was first described 
in 1955 as a “serendipity”. When De Duve and colleagues explored the insulin action 
mechanisms in rat liver tissues, they surprisingly found distinct granular structures containing 
hydrolases (De Duve et al., 1955). Later in 1956, the electron-dense lysosome particles were 
first illustrated by electron microscopy, and the acid phosphatase activity in liver tissue was 
confirmed to be located in a vesicle called lysosome (Essner and Novikoff, 1961; Novikoff et 
al., 1956). Nowadays, it is known that the lysosome contains more than 50 different 
hydrolases involved in catalytic functions. These hydrolases can digest the macromolecules 
that are engulfed by lysosome, including nucleic acids, proteins, carbohydrates and lipids 
(Saftig and Klumperman, 2009). These molecules are generally delivered to lysosomes 
through endocytic or autophagic pathways. 
The endocytic degradation pathway starts from the plasma membrane (PM) and ends at 
lysosomes. The cargos designated for degradation, as well as the recycling lysosomal 
proteins, begin their transportation from the PM to the early endosome (EE) and 
multivesicular body (MVB, also called intermediate or late endosome, LE), which is 
ultimately merged with a lysosome. Besides the PM-mediated endocytic pathway, the newly 




endosomal components such as MVB and EE, followed by delivery to lysosomes for 
degradation (Figure 1) (Saftig and Klumperman, 2009).  
There are several lysosomal-membrane proteins with specific functions in lysosomes. 
Lysosome-associated membrane protein 1 (LAMP1) is involved in maintenance of lysosome 
stability, and both LAMP1 and lysosome-associated membrane protein 2 (LAMP2) guide the 
lysosomal fusion processes with autophagosomes and phagosomes (Andrejewski et al., 1999; 
Huynh et al., 2007). Lysosome integral membrane protein 2 (LIMP2, also known as 
SCARB2) helps the transportation of newly synthesized β-glucocerebrosidase (Reczek et al., 
2007). The vacuolar-type ATPase proton pump in the lysosome membrane is necessary to 
maintain the low pH environment for hydrolases (Marshansky and Futai, 2008). Due to the 
crosstalk of the endocytosis-lysosome network (as shown in Figure 1), the lysosome and LE 
share some common membrane protein markers. For example, LAMP1, LAMP2 and LIMP2 
are preferably located in lysosomes, and CD63 is mainly located in LE (Saftig and 
Klumperman, 2009). These markers can be applied to distinguish different cellular vesicles, 
as exemplified in Paper III. 
Figure 1. Schematic illustration of the interactive network between biosynthetic and 
endocytic pathways. Newly synthesized proteins are transported from the endoplasmic 
reticulum (ER) to the Golgi apparatus. From the trans-Golgi network (TGN), the proteins can 
be transported to the plasma membrane through the constitutive secretory pathway and 
subsequently delivered to lysosomes through endocytosis. Alternatively, the lysosomal 
targeting proteins can be directly delivered to the endosome-lysosomal system. Adapted and 
modified from (Saftig and Klumperman, 2009). 
 
Besides the interaction with endocytosis, the lysosome also interacts with chaperone-
mediated autophagy (CMA), macro- and micro-autophagy (Figure 2) (Dunn, 1994). In CMA, 




heat-shock cognate protein 70 (HSC70) and other co-chaperones (Kaushik and Cuervo, 
2012). Microautophagy is a lysosome-self engulfment process that resembles the endosomal-
sorting complex for MVB formation (Sahu et al., 2011). Macroautophagy is thought to be the 
major type of autophagy, which deploys the double membrane vesicles called 
autophagosomes to lysosomes. Generally, macroautophagy is referred to as autophagy 
(Mizushima and Komatsu, 2011).  
Macroautophagy is initiated under starvation or other stress conditions. Once 
macroautophagy starts to occur, the degradation substrates are sequestered into phagophores 
to form the autophagosome. This autophagosome formation includes three steps: initiation, 
nucleation and expansion (Lamb et al., 2013). The initiation step requires the unc51-like 
kinase (ULK) complex, consisting of ULK1 or ULK2, ATG13, FIP200 and ATG101. The 
activity of the ULK kinase is suppressed by mammalian target of rapamycin complex 1 
(mTORC1). AMP-activated protein kinase (AMPK) can restore the initiation via inhibition of 
mTORC1 and directly facilitate the activation of ULK complex (Alers et al., 2012). Besides, 
the PI3K-AKT signaling pathway can activate the mTOR pathway that leads to autophagy 
suppression (Saiki et al., 2011). Once the ULK complex is phosphorylated and activated, it 
promotes phosphorylation of VPS34 and triggers the formation of the Beclin-1 (BECN1)-
PI3K-VPS34 complex for autophagosome formation (Russell et al., 2013). The BECN1 
complex assists in the binding to the E3-like ATG16L. Subsequently, the ATG16L1-ATG12-
ATG5 complex is recruited by an ubiquitin-like reaction that promotes the autophagosomal 
elongation and lipidation of LC3. The lipidated LC3/ATG8 complex can bind to 
Sequestosome 1 (SQSTM1, also known as p62) to form autophagosomes (Pankiv et al., 
2007). When the autophagosome has been assembled, it fuses with lysosomes to become 
autolysosomes. Finally, the cargos are degraded by lysosomal hydrolases for recycling of 
cellular constituents (Mizushima et al., 2002).  
 
1.1.2 Ubiquitin-proteasome degradation system 
The lysosome pathway was regarded as the major protein degradation system until 1977, 
when a new lysosome-independent and adenosine triphosphate (ATP)-dependent proteolytic 
system was identified in rabbit reticulocytes (Etlinger and Goldberg, 1977). Thereafter, this 
degradation system is described as a highly selective turnover of proteolytic substrates and 
named as the ubiquitin-proteasome system (UPS), which is distinguished from the lysosomal 
degradation system that is used under stress conditions (Ciechanover, 1994).  
The UPS includes two major steps: the protein “tagging” step and the 26S proteasome 
complex proteolytic step. The accuracy of the UPS selection is based on a poly-ubiquitin 
chain tagging towards the degradation candidates. Ubiquitin (Ub) is a small and conserved 
protein with 76 amino acids. It acts as a post-translational modification called ubiquitination 
at lysine residues. Proteins designated for degradation will be covalently bound with one Ub 




ubiquitin-conjugating enzyme (E2) acts as a carrier transferring the ubiquitinated substrate to 
another group of ubiquitin ligases called E3. E3 recognizes the mono-ubiquitin-tagged-
protein and E2 complex, ligates additional Ub to elongate the Ub-tagged chain. The 
minimum requirement for downstream signal is tetra-ubiquitin, which is needed for effective 
proteasomal targeting (Thrower et al., 2000). The diversity of E1 and E2 is limited, but the 
E3 group contains a large number of proteins, which reflects the highly specific system for 
orchestrating protein homeostasis (Ardley and Robinson, 2005).  
Proteasomes in mammals are cylindrical structures, containing the cytosolic 26S trimeric 
complex of 2,000 kilodalton (kDa). The 26S complex consists of one 20S catalytic core 
particle and two 19S cap regulatory subunits (Ciechanover, 2005). The 19S subunit contains 
ATPase active sites and one ubiquitin-binding site. During the degradation process, the 19S 
subunit recognizes the ubiquitin chain, cleaves the ubiquitin tag, partially unfolds the protein 
and translocates the protein into 20S (Finley, 2009; Matyskiela et al., 2013). The 20S core 
particle consists of four subunits (two outer α subunits and two inner β subunits), which are 
seven-base-units ring structures. The β subunit-ring accounts for the ATP-independent 
proteolytic chamber and releases the substrate-derived short polypeptides (Ciechanover, 
2005). An overview of the UPS is illustrated in Figure 2. 
 
1.1.3 Misfolded protein and aggresome 
The correct linear amino acid sequence and subsequent folding pattern warrant the unique 
three-dimensional protein structure, which determine the appropriate protein functions. 
Amino acid mutations or abnormal protein folding can result in misfolded proteins (Ellis and 
Pinheiro, 2002). Misfolded proteins are under surveillance of the molecular chaperones 
system for correction (Ellis, 2006). However, when the critical accumulated level of 
misfolded proteins is reached, aggregated protein complexes and amyloid-like structures can 
be formed. Accumulated misfolded proteins can lead to enormous deleterious outcomes. For 
example, in cystic fibrosis, the F508 deletion mutation leads to misfolding of the cystic 
fibrosis transmembrane conductance regulator (CFTR), abolishing its function (Rubenstein et 
al., 1997). In neurodegenerative diseases, the accumulation of misfolded protein aggregates, 
such as Amyloid β peptide in Alzheimer’s disease, Huntingtin aggregates in Hungtinton’s 
disease and α-Synuclein forming Lewy bodies in Parkinson’s disease disrupts the cellular 
homeostasis and contributes to the pathogenesis of the disease (Chiti and Dobson, 2006). 
Cells employ the aforementioned diverse protein degradation systems to clear the 
misfolded proteins, including the UPS and the autophagy-lysosome systems. If the misfolded 
protein clearance has failed, the accumulated misfolded proteins will generally aggregate to 
form paranuclear inclusion bodies termed aggresomes (Kopito, 2000). An aggresome is a 
cytoplasmic structure formed by the intermediate filaments at the microtubule organizing 
center (MTOC), which sequesters misfolded proteins for subsequent degradation by 




formation. The first involves the microtubule-associated histone deacetylase 6 (HDAC6), 
which has been identified to bridge between poly-ubiquitin tagged proteins and the dynein 
motor complex. This binding contributes to the transportation of misfolded proteins towards 
the MTOC via the dynein-motor complex (Kawaguchi et al., 2003). The second pathway 
involves the co-chaperone Bcl-2-associated athanogene 3 (BAG3). This protein interacts with 
both the HSP70-substrates and the microtubule-motor dynein, which loads misfolded protein 
onto the dynein motor complex. Unlike HDAC6-mediated pathway, substrate ubiquitination 
is not essential for BAG3-mediated aggresome formation (Gamerdinger et al., 2011). 
Commonly, both pathways rely on the microtubule and dynein-motor complex to deliver the 
misfolded proteins to the MTOC. 
 
Figure 2. An overview of the two mammalian cellular degradation systems. The 
lysosome-mediated pathways, which include endocytosis, chaperone-mediated autophagy, 
microautophagy and macroautophagy are shown at the top and the ubiquitin-proteasome 





1.1.4 Protein degradation systems in cancers 
The protein degradation systems involved in cancer are important from several aspects 
related to: (1) Modulation of the expression level of key cancer regulators, (2) Contribution to 
the pathophysiological signaling pathways involved in tumor development and progression, 
and (3) Their possible use as targets in therapeutic interventions. 
Besides the involvement in neurodegenerative disorders (Goldberg, 2003), the lysosome-
autophagy system has also been extensively studied in cancer (Levine and Kroemer, 2008). 
However, autophagy is still heavily debated concerning its possible dual-role in tumor 
promoting as well as suppressing functions (Jin and White, 2007; Kroemer et al., 2010; 
Levine and Kroemer, 2008; Levy et al., 2017). There is strong scientific evidence that 
autophagy is a bona fide tumor suppressor system. For example, heterozygous deletion of 
Becn1 and homozygous deletion of Bif-1 (an interacting protein of Becn1, which is required 
for autophagosome formation) promotes spontaneous tumorigenesis (Qu, X. et al., 2003; 
Takahashi et al., 2007). Additionally, autophagy deficiency can also jeopardize its 
surveillance function and promote genomic instability by accumulation of p62 that inhibits 
the RNF168 E3 ligase activity for histone H2A ubiquitination, leading to impaired DNA 
repair (Eliopoulos et al., 2016; Wang et al., 2016). Alternatively, autophagy can also favor 
tumor cell survival by sustaining stress conditions, such as nutrient deprivation, misfolded 
protein accumulation and pathogen invasion (Kroemer et al., 2010). For example, silencing of 
macroautophagy can induce apoptosis and sensitize cells under nutrient starvation (Boya et 
al., 2005). Nowadays, the majority of the clinical trials for targeting autophagy in cancer are 
based on autophagy inhibition (Levy et al., 2017).  
As a key protein degradation system, it is not surprising that the UPS plays a vital role in 
cancer. The UPS system particularly regulates the protein turnover of several key players 
involved in tumorigenesis, such as the cell cycle family members p53, c-Jun, c-Myc, and NF-
κB (Adams, 2003, 2004; Ciechanover et al., 1991). For instance, the NF-κB pathway requires 
the UPS 26S complex to degrade its inhibitor IκB in order to regulate the pro-survival 
pathways (Palombella et al., 1994). Besides, the expression level of the tumor suppressor p53 
is under the balance of UPS degradation (Maki et al., 1996). E3 ligases from the UPS also 
participate in cancer development via its ubiquitination function. The MDM2 oncogene has 
been confirmed as an E3 ligase that promotes ubiquitination of p53 for degradation via its 
RING ligase domain (Haupt et al., 1997; Honda and Yasuda, 2000; Maki et al., 1996). Other 
examples include the VHL and BRCA1 E3 ligases. Loss-of-function mutations of VHL leads 
to degradation failure of hypoxia-inducible factor (HIF) proteins in renal clear cell carcinoma 
(Gunaratnam et al., 2003), while the E3 ubiquitin ligase activity of BRCA1 provides signals 
for DNA repair (Wu et al., 2008).  
The UPS has also been shown to be involved in virus-induced carcinogenesis, such as 
the F-box and WD repeat domain-containing 7 (FBXW7) E3 ligase that promotes 
degradation of viral oncoprotein in Merkel cell carcinoma, which will be discussed in more 




substrates, such as c-Myc and cyclin E, supporting its tumor suppressor function in human 
cancers (Welcker and Clurman, 2008; Yeh et al., 2018). The UPS has been reported to have 
higher activity in many cancer types (Arlt et al., 2009; Chen and Madura, 2005; Kumatori et 
al., 1990), which might be due to altered protein requirement for abnormal proliferation, 
apoptosis status and stress conditions. Therefore, protein degradation systems could provide 
multiple potential therapeutic targets in cancer medicine.  
 
1.2 MERKEL CELL POLYOMAVIRUS AND MERKEL CELL CARCINOMA 
1.2.1 Merkel cell carcinoma origin and diagnostic markers 
MCC is a rare but aggressive type of skin cancer, which was first described as ”trabecular 
tumor of the skin” by Cyril Toker in 1972 (Toker, 1972). This tumor type is believed to 
originate from the mechanoreceptor Merkel cells, based on three cellular features: the 
presence of neurosecretory granular (NG) structures; the sharing of identical neuroendocrine 
markers, e.g. chromogranin A and synaptophysin (Tang and Toker, 1978); and expression of 
Merkel cell-like cytoskeleton markers, e.g. cytokeratin 20 (Moll, 2006). Examples of NG and 
whorl-like intermediate filament structure are shown in Figure 3. Several arguments have 
been put forward questioning whether the Merkel cell is the origin of MCC. Firstly, Merkel 
cells are located in the base of the epidermis, while MCC typically develops in the dermis 
(Sibley et al., 1985). Secondly, some immunohistological markers are expressed in MCC, 
such as the neural cell adhesion molecular L1, the mucin-like adhesion protein CD24 and 
receptor tyrosine kinase c-KIT, but which are not detected in Merkel cells (Deichmann et al., 
2003; Su et al., 2002a). Thirdly, numerous mitoses are found in MCC, which is opposed to 
the terminally differentiated and post-mitotic nature of Merkel cells (Moll et al., 1996). 
Lastly, different mouse models using Merkel cell-specific drivers fail to generate MCC 
(Shuda et al., 2015; Spurgeon et al., 2015; Verhaegen et al., 2017; Verhaegen et al., 2015).  
On the other hand, Zur Hausen et al. proposed early B-cells as the cellular origin of 
MCC based on the expression of early B-cell lineage markers such as the terminal 
deoxynucleotidyl transferase and paired box gene 5 (PAX5), and the evidence of clonal 
immunoglobulin chain rearrangement (Zur Hausen et al., 2013). Furthermore, chronic 
lymphocytic leukemia (CLL) is frequently associated with MCC (Tadmor et al., 2011), and 
concurrent development of MCC and CLL in the same patients has also been reported 
(Barroeta and Farkas, 2007; Khezri et al., 2011; Pan et al., 2014; Popovic et al., 2014). 
Interestingly, Merkel cell polyomavirus (MCPyV) is present in 27% of CLL, and mutation of 
the viral large T-antigen and viral integration into the host DNA has also been detected in a 
subset of CLL (Pantulu et al., 2010).  
Intriguingly, Liu et al. demonstrated that the dermal fibroblast is the target of MCPyV 
infection, suggesting its putative origin for MCPyV-positive MCC (Liu, W. et al., 2016). 
Hitherto, the MCC cell origin is still uncertain, and viral-positive and -negative MCC may 





Figure 3. Electron microscopic image of WaGa MCC cell line. (A) A representative cell 
showing typical paranuclear whorl-like intermediate filament structures. (B) Enlargement of 
the yellow box in (A), illustrating the location of whorl-like intermediate filament structure 
(as indicated by arrow) adjacent to centriole (C) and surrounded by lysosomes (Ly), 
mitochondria (M) and neurosecretory granule (NG). Scale bar: 10 µm in (A) and 2 µm in (B). 
 
MCC presents as a rapidly growing red-violet nodule or mass at cutaneous layers, 
including dermal and deeper region (Becker et al., 2017). Histopathological examination with 
hematoxylin-eosin staining typically shows a morphology with small round blue cells and a 
high number of mitoses (Harms, 2017). However this morphology is also present in other 
tumor types, such as small cell lung cancer (SCLC), and Ewing sarcoma. Hence further 
confirmation with immunohistochemical analyses of specific markers is essential (Bichakjian 
et al., 2018). The recommended panel of diagnostic markers is listed in Table 1, which 
include cytoskeletal keratins (CK20 and CK7), neuroendocrine markers (neuron-specific 
enolase, chromogranin A and synaptophysin), thyroid transcription factor 1, huntingtin-
interacting protein 1 (HIP1), S100, leucocyte common antigen and the MCPyV large T-


























Table 1. Immunohistochemical markers for differential diagnosis of MCC and other 
malignancies with small round blue cells.  
 MCC Lymphoma Melanoma SCLC 
CK20 + - - - 
CK7 - - - + 
NSE + - - +/- 
CgA +/- - - +/- 
HIP1 + +/- - - 
TTF-1 - - - + 
S100 - - + - 
LCA - + - - 
MCPyV LT + - - - 
CK20, cytokeratin 20; CK7, cytokeratin 7; NSE, neuron-specific enolase; CgA, 
chromogranin A; HIP1, huntingtin-interacting protein 1; TTF-1, thyroid transcription factor 
1; LCA, leucocyte common antigen. MCC, Merkel cell carcinoma; SCLC, small cell lung 
cancer. + = presence, - = absence, +/- = presence or absence of the staining marker. Adapted 
from Lebbe et al., 2015. 
 
1.2.2 MCC incidence, risk factors and mortality 
The incidence of MCC has increased more than 4-fold (1.5 to 7 per million) from 1986 to 
2013 in the United States (Hodgson, 2005; Paulson et al., 2018). About 2,500 new cases are 
diagnosed each year in the United States and Europe (Paulson et al., 2018; Stang et al., 2018). 
In Sweden, the incidence has risen from 1.1 to 1.9 per million from 1993 to 2012, and 47 new 
cases were reported in 2012 (Zaar et al., 2016). A similar ascending trend has been reported 
worldwide, including Finland (Kukko et al., 2012), France and Australia (Fondain et al., 
2018; Youlden et al., 2014). 
The risk factors for MCC include age, gender, fair skin and ultraviolet (UV) exposure. 
MCC occurs slightly more common in male (more than 54%) than female in the United 
States, Finland and Sweden, especially in older population (Paulson et al., 2018; Sihto et al., 
2011; Zaar et al., 2016). The average and median age of MCC diagnosis is above 75 years 
(Fondain et al., 2018; Paulson et al., 2018; Sihto et al., 2011; Zaar et al., 2016). The incidence 
(per million inhabitants per year) rises exponentially with age: from 1 in the age group 40-44 
years, to 10 in the group 60-64 years and to 98 above 85 years of age (Paulson et al., 2018). 
MCC predominantly occurs in the white population (94.9%), which might be explained by 
the fact that skin pigmentation protect skin from UV damage (Albores-Saavedra et al., 2009). 
The association between UV radiation and MCC has been well documented. The MCC 
incidence is positively associated with increasing UVB (one of the UV rays with 280-315 nm) 
index in the United States (Agelli and Clegg, 2003). MCCs are commonly, but not 
exclusively, located in sun-exposed skin areas, such as the head, neck and extremities 




incidence of MCC was double in Queensland, Australia, as compared to elsewhere in the 
world (Youlden et al., 2014); this is likely due to the higher intensity of sunlight exposure.  
In addition, immune deficiency has a crucial etiological role in MCC. The incidence of 
MCC increases sharply among individuals who received therapeutic immunosuppression 
after solid organ transplantation (Clarke et al., 2015). Acquired immune-deficiencies, such as 
leukemia, lymphoma and acquired immune deficiency syndromes, are also associated with 
higher risk of MCC development (Engels et al., 2002; Heath et al., 2008). The combination of 
aging, UV exposure and immune-deficiencies also indicate the key role of immune 
surveillance for the prevention of MCC. Interestingly, MCC bears remarkable similarities to 
other tumors with a viral etiology, such as Kaposi sarcoma, both of which commonly occur in 
older and immunosuppressed individuals (Engels et al., 2002; Sihto et al., 2009). 
Staging of MCC is also based on the TNM classification of Malignant Tumors, in which 
“T” stands for the size of the primary tumor, “N” for regional lymph node involvement and 
“M” for distant metastasis. For MCC, primary tumors with a diameter of ≤ 2 cm, > 2 but ≤ 5 
cm, and > 5 cm are classified as T1, T2 and T3, respectively. MCCs with deep invasion (such 
as bone and muscle) will be classified as T4 (Lebbe et al., 2015). Due to limited experience 
of the disease and the lack of early diagnostic markers, MCC patients are usually diagnosed 
at the advanced stage. The staging and 5-year overall survival of MCC is shown in Table 2 
(Harms et al., 2016; Lebbe et al., 2015). Over 40% of MCC patients develop a recurrence 
within a median time of 9 months, and the median survival for patients with distant 
metastasis is approximately 9 months (Allen et al., 2005). 
Table 2. MCC staging and corresponding 5-year overall survival  
Stage T N M 5-year overall survival (%) 
O TIS N0 M0  
IA T1 pN0 M0 79 
IB T1 cN0 M0 60 
IIA T2/T3 pN0 M0 55 
IIB T2/T3 cN0 M0 49 
IIC T4 N0 M0 47 
IIIA Any T N1a M0 40 
IIIB  N1b/N2 M0 27 
IV  Any N M1 14 
TIS, tumor in situ; T1, primary tumor diameter ≤ 2 cm; T2, between 2 cm and 5 cm; T3, > 5 
cm; T4, deep invasion; N0, no regional node metastasis; cN0, nodes not clinically detectable 
but no pathologic examination, pN0, nodes negative both clinically and by pathologic 
examination; N1a, micrometastasis; N1b, macrometastasis; N2, in transit metastasis; M0, no 
evidence of distant metastasis; M1, metastasis beyond regional lymph nodes. Adapted from 
Lebbe et al., 2015; Harms et al., 2016. 
 
1.2.3 Merkel cell polyomavirus and association with MCC 
The Merkel cell polyomavirus (MCPyV) was first discovered in MCC by whole-




in 8 out of 10 MCC (Feng et al., 2008). The full-length genome is 5,387 base-pairs, and the 
genome map with corresponding transcripts are shown in Figure 4 (DeCaprio and Garcea, 
2013). It harbors a non-coding control region (NCCR) where the transcription starts with 
corresponding early and late promoter. The genome is divided into the early region for viral 
antigens and the late region for viral capsid proteins (Topalis et al., 2013). 
 
Figure 4. MCPyV genome map with different spliced variants from the early and late 
regions. NCCR, non-coding control region; sT, small T-antigen; LT, large T-antigen; VP, 
viral protein. Adapted from DeCaprio and Garcea, 2013.  
 
Later, several studies with larger cohorts have confirmed that MCPyV is found in the 
majority of MCC, ranging from 75% to 89% (Becker et al., 2009; Feng et al., 2008; 
Foulongne et al., 2008; Kassem et al., 2008; Prieto Munoz et al., 2013). Worldwide, 
MCPyV+ MCC is also the dominant type except in Oceania areas (Kuwamoto, 2011).  
Interestingly, MCPyV infection is also widespread in the general population. 
Substantial MCPyV antibody titers have been detected in newborns, children and adults 
(Chen et al., 2011; Martel-Jantin et al., 2013; Tolstov et al., 2009). An age-dependent 
prevalence of MCPyV infection has been observed based on sera antibody test. The 
prevalence is below 40% before 5 years of age, but linearly increases to above 80% for the 
group aged above 50 (Tolstov et al., 2009). However, MCPyV integration into the host 
genome is only found in MCC tumors (Feng et al., 2008; Sastre-Garau et al., 2009) and a 
subset of CLL (Pantulu et al., 2010). Numerous reports have suggested that the viral genome 




same MCPyV mutated sequence and integration in primary tumor and distant metastasis of 
the same patient (Laude et al., 2010; Sastre-Garau et al., 2009; Shuda et al., 2009).  
 
1.2.4 Role of MCPyV oncoproteins 
Similar to other polyomaviruses, MCPyV encodes four different viral tumor antigens (T 
antigens), including large T, small T (sT), 57 kT and alternative T antigen open reading frame. 
Among these T-antigens, sT and LT are regarded as the main tumor-driven proteins (Kwun et 
al., 2009; Shuda et al., 2009). The functional domains of these two transcripts are shown in 
Figure 5.  
The majority of MCC tumors harbor an integrated MCPyV genome with a mutation in 
the LT, leading to expression of truncated LT and intact sT. Mutations of LT are found in 
exon 2 of LT and downstream of the Rb-binding domain (Figure 5), which lead to 
elimination of the helicase domain of LT for viral replication (Shuda et al., 2008). Silencing 
of both LT and sT can lead to growth suppression and cell cycle arrest, indicating that both T-
antigens are essential for MCC growth. Furthermore, both T-antigens can also promote 
neoplastic transformation and tumor development in vivo (Houben et al., 2010; Shuda et al., 
2008; Shuda et al., 2015; Spurgeon et al., 2015; Verhaegen et al., 2015). 
LT and sT share the common DnaJ domain at the amino-terminus, which comprises the 
conserved CR1 and HSC70 binding motifs for viral DNA replication and cell growth through 
induction of E2F target genes (Feng et al., 2008; Houben et al., 2015; Kwun et al., 2009). LT 
has a MCPyV unique region (MUR), which contains the retinoblastoma (Rb) binding, 
Vam6p binding and nuclear localization signal (NLS) motif. The Vam6p interaction disrupts 
cellular lysosome trafficking (Liu et al., 2011) and protein degradation system (Papers III 
and IV). The MUR also contains the LXCXE motif that binds Rb, which can sequester Rb 
from E2F, ultimately leading to cell cycle progression (Shuda et al., 2008). The NLS was 
initially thought to be preserved in the truncated LT of MCC (Nakamura et al., 2010); 
however it is now clear that this motif is not always preserved in the tumors and is not 








Figure 5. Functional domains of MCPyV LT and sT. At the top is an illustration of LT 
with different functional domains. The numbers below refer to the positions of amino acid. 
Mutations frequently occur downstream of Rb binding site. The truncated LT of the three 
MCPyV+ MCC cell lines (WaGa, MKL-1 and MKL-2) used in this thesis is illustrated in the 
middle panel of the figure. In addition, the two plasmids expressing full-length LT (LTco) 
and truncated LT (LT339) are also shown. At the bottom is the sT, which has the common 
DnaJ domain as the LT and a unique region. NLS, nuclear localization signal; MUR, MCPyV 
unique region; OBD, origin binding domain; LSD, LT-stabilization domain; PP2A/4C, 
protein phosphatase 2A/4C. 
 
The MCPyV sT has a special domain called LT-stabilization domain (LSD), which is 
responsible for inhibition of FBXW7 and thus stabilization of the expression of FBXW7-
degradation substrates, such as LT, Myc and cyclin E (Kwun et al., 2013) and for induction 
of genomic instability (Kwun et al., 2017). Besides, the LSD domain also targets 4E-BP1 to 
preserve its hyperphosphorylation and release eIF4E for activation of cap-dependent protein 
translation (Shuda et al., 2011). sT also inhibits the NF-κB essential modulator related 
transcription via the direct interaction with PP4C (Griffiths et al., 2013). Unlike SV40 sT, the 
PP2A targeting by MCPyV sT is not required for cellular transformation (Kwun et al., 2015). 
Moreover, sT also participates in several biological processes, such as induction of cell 




regulation of Rho-GTPase (Stakaityte et al., 2018), as well as increase aerobic glycolysis via 
monocarboxylate transporter for transforming activity (Berrios et al., 2016).  
Interestingly, the full-length LT has distinct functional roles as compared to truncated LT. 
The carboxyl-terminal helicase-containing region of LT can activate cellular DNA damage 
response via the p53 pathway and suppress cell growth (Cheng et al., 2013; Li, J. et al., 2013). 
The inhibitory effect on proliferation can be rescued by a dominant-negative p53 inhibitor (Li, 
J. et al., 2013). These findings indicate that selection of truncated LT by elimination of the 
helicase domain is important for MCC tumor development. 
 
1.2.5 Genetic differences between virus- and non-virus associated MCC 
Generally MCC can be divided into two groups: MCPyV-positive (MCPyV+) and MCPyV-
negative (MCPyV-). Genome-wide analyses have shown that MCPyV- MCC has much 
higher frequencies of somatic mutations than MCPyV+ MCC, and that the mutations in the 
MCPyV- tumors are associated with UV-mediated signatures (Harms et al., 2015; Starrett et 
al., 2017). The mutation signatures indicate dominant characteristics of C-to-T mutations, 
resulting from the UV-induced pyrimidine dimers. Besides, the high mutation burden in 
MCPyV- MCC is also in agreement with an UV etiology in MCPyV- MCC (Starrett et al., 
2017).  
Mutations of RB1 and TP53 are frequently found in MCPyV- MCC, while mutations of 
these two genes are uncommon in MCPyV+ MCC (Goh et al., 2016; Harms et al., 2015; 
Paulson et al., 2009). Yet, RB and p53 are inactivated by the viral LT (Park et al., 2019; 
Rodig et al., 2012; Starrett et al., 2017). Other pathogenic mutations are also detected in 
MCPyV- MCC, such as loss-of-function mutations of the tumor suppressor PTEN, and genes 
involved in chromatin-modification (ASXL1, MLL2 and MLL3), DNA-damage checkpoint 
and repair systems (ATM, MSH2, MLH1, BRCA1 and BRCA2) and WNT signaling (APC, β-
catenin and LEF-1) (Goh et al., 2016; Harms et al., 2015; Paulson et al., 2009; Starrett et al., 
2017). In addition, gain-of-function mutations in JUN, EGFR and MYCL1 have been reported 
in MCPyV- MCC (Paulson et al., 2009; Starrett et al., 2017).  
Gene expression profiling has revealed upregulation of several oncogenes in MCC, 
including FYN, AKT1, AKT3, SOX2, BCL2, MYCL1, VEGFA, ATOH1, HIP1 and c-KIT, as 
compared to cutaneous squamous cell carcinoma, and downregulation of genes involved in 
Hedgehog signaling (GLI1, GLI2, PTCH1 and PTCH2) as compared to basal cell carcinoma 
(Harms et al., 2013; Paulson et al., 2009).  
Distinct gene expression profiles are associated with MCPyV status in MCC (Harms et 
al., 2013) (Harms et al., 2015; Starrett et al., 2017). MCPyV- tumors show upregulation of 
Notch family signaling genes (NOTCH1, NOTCH2, DLL1, CTBP2, HES1, JAG2 and JAG1), 
receptor tyrosine kinases (VEGFA, PDGFA, FGFR2), DNA damage response genes (MSH2 




(GABRB3, KCNN1, KCNN2 and KCNQ3) and cell cycle regulators (CCNA1 and CCND1) are 
found in MCPyV+ MCC. 
 
1.2.6 The immune escape of MCC 
The immune profiles are also distinct between MCPyV+ and MCPyV- MCCs. In MCPyV+ 
MCCs, higher numbers of tumor-infiltrating immune cells are observed, concerning CD3+, 
CD8+, CD16+, FoxP3+ and CD68+ cells. However, high numbers of intratumoral CD3+ and 
CD8+ T-cells favor patient survival regardless of viral status (Sihto et al., 2012). Similarly, 
using transcriptomic profiling, Harms et al., identified higher levels of immune response 
genes, such as CD3G, CD3D, ZAP70 and IGHM, in MCPyV+ MCCs, indicating the presence 
of tumor-infiltrating lymphocytes (TILs). Indeed, they verified higher numbers of CD8+ 
lymphocytes in MCPyV+ MCCs (Harms et al., 2013). However, impaired T-cell activation 
and T-cell exhaustion have been observed in MCC TILs, implicating immune evasion by 
MCC (Dowlatshahi et al., 2013) (Walsh et al., 2016). Importantly, tumor-specific T-cells can 
be stimulated for activation, expansion and antitumor function (Dowlatshahi et al., 2013) 
(Gavvovidis et al., 2018).  
 Together, these observations indicate immune escape in MCC, however the 
mechanisms of immune evasion in MCC remain unclear. Nevertheless, these findings have 
driven the rationale for using immune checkpoint inhibitors in MCC treatment (Nghiem et 
al., 2016; Topalian et al., 2020). 
 
1.2.7 Clinical management of MCC 
According to the newest National Comprehensive Cancer Network (NCCN) guidelines 
(Bichakjian et al., 2018), after physical examination of suspicious lesion on the skin, 
histopathological evaluation of the lesion, including the regional skin and lymph node (LN), 
will be performed using the immune-panel markers as described in Section 1.2.1 and Table 1. 
Sentinel lymph node biopsy (SLNB) is highly recommended for determination of subclinical 
nodal diseases, even if LN is negative. If LN and SLNB are negative, adjuvant radiotherapy 
treatment will be performed on the primary tumor site. If LN or SLNB is positive, 
comprehensive imaging studies, such as magnetic resonance imaging/ computed tomography 
(MRI/CT) with specific region or whole body positron emission tomography (PET)/CT scan, 
should be applied to detect regional or distant metastasis. Single therapy or a combination of 
surgical excision, radiation therapy, and systemic therapy such as chemotherapy and 
immune-checkpoint inhibitor (anti-PD1 or anti-PD-L1) may be applied. The surgical margin 
is still under discussion, but commonly 1-2 cm is recommended (Becker et al., 2017; 
Bichakjian et al., 2018). In those cases with distant metastasis, immunotherapy or other 
clinical trials with therapies shown to be effective for metastatic cancers will be preferred 




1.3 CELLULAR DEGRADATION SYSTEMS AND VIRAL PATHOGENESIS 
Since the viral genome is usually limited in size, viruses exploit the host cellular machineries 
to complete their life cycle, including viral entry, genome replication, translation, assembly 
and virion release. The cellular degradation systems, including the lysosome-autophagy and 
the UPS, are important regulators of viral pathogenesis. 
 
1.3.1 Viral infection and cellular degradation systems 
Virus and other pathogens can protect themselves by harnessing the host degradation systems 
during infection (Kirkegaard et al., 2004). Disruption of lysosome-autophagosome fusion and 
inhibition of proteasome for viral infection has been reported in several RNA viruses. For 
example, blocking lysosome with H+-ATPase inhibitor bafilomycin A1 and inhibiting 
proteasome with MG-132 lead to higher infectivity of Human Immunodeficiency Virus Type 
1 in vitro (Wei et al., 2005). Administrating the glycopeptide antibiotic to antagonize the 
Cathepsin L lysosomal hydrolase can block the viral entry for Ebola virus and two other 
Coronaviruses (MERS-CoV and SARS-CoV) (Zhou et al., 2016). Ding et al. illustrated that 
the Human Parainfluenza virus 3 can utilize the viral phosphoprotein to disrupt the host 
SNARE proteins, resulting in autophagy disruption and accumulation of viral productions 
(Ding et al., 2014). Similarly, DNA virus such as Hepatitis B virus (HBV) has also been 
shown that its replication is increased upon inhibition of autophagosome-lysosome fusion 
(Lin et al., 2019). 
 
1.3.2 Viral oncogenesis and ubiquitin-proteasome system 
Oncogenic viruses can manipulate multiple targets in the UPS for oncogenesis (Masucci, 
2004). The first evidence was demonstrated in Human papillomavirus (HPV). HPV E6 
oncoprotein can bind to E6AP, a cellular E3 ubiquitin ligase involved in the UPS, which 
directs E6AP to ubiquitinate p53 for proteasomal degradation (Scheffner et al., 1993; 
Scheffner et al., 1990).  
Subsequently, several viral oncoproteins have also been demonstrated to hijack 
proteasomal degradation by targeting different components of the UPS (Masucci, 2004). In 
hepatitis B virus (HBV), its oncoprotein HBV X antigen (HBx) binds to the 20S subunit and 
the 19S subunit of proteasome that prevents degradation of c-JUN for cellular transformation 
(Zhang et al., 2000). In Epstein-Barr virus (EBV), the glycine-alanine repeat domain of the 
EBV nuclear antigens 1 (EBNA-1) can capture 19S proteasome subunit that blocks UPS 
substrate degradation (Levitskaya et al., 1995). In addition, EBNA-1 also competes for the 
binding of ubiquitin specific protease 7 (HSP7) to MDM2 that leads to stabilization of 
MDM2, which targets p53 for proteasomal degradation, resulting in B-cell immortalization 
and tumorigenesis (Boutell and Everett, 2003; Saridakis et al., 2005). In human adenoviruses, 




proteasome degradation of p53 (Querido et al., 2001). In MCC, the LSD domain of MCPyV 
sT directly disrupts the FBXW7 E3 ligase to stabilize the LT and other oncogenic substrates 
for promoting transformation (Kwun et al., 2013) and induces genome instability (Kwun et 
al., 2017). 
 
1.3.3 Viral oncogenesis and aggresome-autophgay 
Tumor viruses have also been reported to target the autophagy-aggresome system for 
tumorigenesis. All the seven known human oncogenic viruses are tightly linked to autophagy 
system (Vescovo et al., 2020), some of the examples are briefly described below.  
Mattoscio et al. demonstrated that HPV E6 and E7 suppress autophagy by disrupting 
autolysosome formation that leads to upregulation of UBC9 for HPV-mediated tumorigenesis 
(Mattoscio et al., 2017). UBC9 is the key enzyme of the Small Ubiquitin-like Modifier 
(SUMO) pathway, in which its expression progressively increases during progression in both 
HPV-associated cervical and head and neck tumorigenesis (Mattoscio et al., 2015; Mattoscio 
et al., 2017). 
As the major etiology for over 80% of hepatocellular carcinoma (HCC) (Zamor et al., 
2017), both HBV and HCV can modulate autophagy for HCC development (Tarocchi et al., 
2014; Vescovo et al., 2012). Although both viruses have been demonstrated to induce 
autophagy during infection, autophagy evasion has been observed in both HBV and HCV-
associated cancers (Lan et al., 2014; Vescovo et al., 2012). Qu et al. provides the first 
evidence that autophagy suppression can promote HCC tumorigenesis, in which they show 
that heterozygous deletion of Becn1 promotes tumorigenesis in HBV transgenic mice (Qu, 
X.P. et al., 2003), indicating the importance of autophagy evasion in HBV-mediated 
tumorigenesis. The viral oncoprotein HBx can impair lysosomal maturation, which results in 
inhibition of autophagic degradation (Liu et al., 2014). Inhibition of autophagic degradation 
will lead to accumulation of p62. Concordantly, accumulation of p62 level has been observed 
in HCC, including HCV-associated HCC, and that promotes tumorigenesis (Saito et al., 
2016; Umemura et al., 2016). 
In MCC, we demonstrate that the MCPyV T-antigens can suppress autophagy through 
miRNAs and an oncogenic receptor tyrosine kinase (RTK). The truncated LT and sT of 
MCPyV can induce miR-375, miR-30a-3p and miR-30a-3p levels through the viral DnaJ 
domain at the N-terminus, which directly targets ATG7, p62 and BECN1 (Paper II). The 
truncated LT can also promote intracellular retention and stabilization of c-KIT via its Vam6p 
interaction, which promotes the binding of c-KIT to BECN1 and recruitment of BCL2 
complexes for autophagy suppression (Paper III). Induction of autophagy regulates cell 
growth and destabilizes the LT oncoprotein (Papers II and III), suggesting the importance of 




Some viral proteins can also promote aggresome formation during tumorigenesis. Such 
an example is found in adenovirus. The E1B-55K and E4orf3 proteins of the adenovirus can 
promote cellular transformation. Interestingly, these viral proteins can induce aggresome 
formation (Blanchette et al., 2013; Liu et al., 2005) and sequester different tumor suppressors 
into aggresomes, including p53 (Zhao and Liao, 2003), Mre11, a factor involved in DNA 
repair (Araujo et al., 2005; Liu et al., 2005) and SSBP2, a tumor suppressor in both leukemia 




MicroRNAs (miRNAs) are a group of non-coding single-stranded ribonucleic acids (RNAs) 
with a length of about 22 nucleotides (nts). lin-4 is the first miRNA described in 
Caenorhabditis elegans that control developmental timing through suppression of lin-14 
messenger-RNA (mRNA) (Lee et al., 1993; Wightman et al., 1993). Generally, miRNAs can 
affect gene expression by imperfect pairing to mRNA.  
 
1.4.1 miRNA biogenesis and functional mechanisms 
The primary transcript of miRNA (pri-miRNA) is generally transcribed by RNA polymerase 
II from miRNA gene in the nucleus (Lee et al., 2004). Pri-miRNAs can be several kilobases 
in length containing a stem-loop structure; the secondary structure navigates the pri-miRNA 
to anchor into the microprocessor complex formed by Drosha and DGCR8. In this complex, 
pri-miRNA is cropped to produce a hairpin precursor-miRNA (pre-miRNA) with a length of 
about 70 nts. The pre-miRNA is then transported to the cytoplasm via Exportin-5. After 
exporting out from the nucleus, pre-miRNA interacts with the Dicer RNase III enzyme and 
TARBP2 in which the loop region is cleaved, releasing a ~22 nts double-stranded RNA.  This 
duplex is loaded onto Argonaute complex and forms RNA-induced silencing complex 
(RISC). Only one strand is preserved based on the thermodynamic stability, the other strand 
is named passenger strand and is usually degraded. Finally, the mature single-stranded 
miRNA is then guiding the RISC to search for its target mRNA (Lee et al., 2003; Lund et al., 
2004; Miyoshi et al., 2005).  
In human, the miRNA-mRNA interaction is commonly imperfect pairing, which can 
lead to translational repression or mRNA degradation (Bartel, 2004; Mortensen et al., 2011). 
The mechanistic details of how miRNAs inhibit translation are still unclear, but some studies 
have indicated that the repression step occurs at the translation initiation and/or elongation 
(Petersen et al., 2006; Pillai, 2005). In the case when miRNAs perfectly bind to mRNA, it 
normally leads to endonucleolytic cleavage of mRNA, however this mechanism is 
uncommon in mammals (Chen, 2004; Valencia-Sanchez et al., 2006; Yekta et al., 2004). 




increase gene expression. For example, the HCV RNA expression could be positively 
regulated at multiple sites by the liver-specific miR-122 (Jopling et al., 2008; Jopling et al., 
2005; Li, Y. et al., 2013).  
Besides the interaction between miRNA and mRNA, miRNAs can also interact with 
non-coding RNAs. For example, mouse miR-709 directly binds to its recognization site of 
mir-15a~16-1 to disturb the maturation (Tang et al., 2012). On the other hand, let-7 can bind 
to its own primary transcript and promote autoregulation of its processing (Zisoulis et al., 
2012). One miRNA can regulate multiple mRNAs, while multiple miRNAs can coordinately 
target a single mRNA (Bartel, 2004; Zhou et al., 2013), indicating the complexity of miRNA 
regulatory network.  
 
1.4.2  miRNAs in cancer 
The first cancer-related miRNA study was published in 2002, demonstrating the frequent 
deleted and down-regulated miRNAs (miR-15a and miR-16) in CLL (Calin et al., 2002). 
Calin et al. also revealed that many miRNA genes are located in fragile sites and/or cancer-
related genomic region (Calin et al., 2004). Subsequently, numerous studies discovered many 
cancer-associated miRNAs in different cancer types (Calin and Croce, 2006).  
The first oncogenic miRNA was discovered in B-cell lymphoma called mir-17~92 
cluster (He et al., 2005). This miRNA cluster is frequently amplified and overexpressed in 
hematological malignancies and solid tumors. He et al. provided the direct evidence that this 
miRNA cluster is oncogenic using a B-cell lymphoma mouse model (He et al., 2005). In 
addition, overexpression of this miRNA cluster can promote Notch1-induced T-cell acute 
lymphoblastic leukemia through targeting multiple genes, including Bcl2 family and PTEN 
(Mavrakis et al., 2010). Furthermore, this cluster can promote cellular proliferation in human 
lung cancer, and inhibits TGF-β pathway in neuroblastoma (Hayashita et al., 2005; Mestdagh 
et al., 2010).  
miRNAs can act as oncogenes or tumor suppressors in different cancer types (Zhang et 
al., 2007). For example, miR-223 has been demonstrated to function as an oncogene in 
several cancer types (Kurashige et al., 2012a; Laios et al., 2008; Li, J.H. et al., 2012; Petrocca 
et al., 2008a; Zhang et al., 2014), including testicular germ cell tumor in Paper I. However, 
this miRNA can also function as a tumor suppressor in lung cancer (Luo et al., 2019), 
nasopharyngeal cancer (Gao and Xiong, 2018) and prostate cancer (Kurozumi et al., 2016).  
Furthermore, miRNA also participates in diverse oncogenic processes. A subset of 
miRNAs is under the regulation of p53. For example, expression of miR-34 family (miR-34a, 
miR-34b and miR-34c) is transcriptionally regulated by p53 in response to DNA damage 
response (DDR), which plays important role in cell proliferation, apoptosis and epithelial 




regulated by miRNAs, such as miR-125b and miR-504 (Hu et al., 2010; Le et al., 2009), 
suggesting the importance of miRNAs in p53 network.  
Besides miR-34, miR-24 and miR-138 are regulated by DDR and both miRNAs target 
the histone H2A variant (H2AX) to recruit the DNA repair factors (Lal et al., 2009; Wang et 
al., 2011). In addition to DDR, some miRNAs are regulated by hypoxia. A well-known 
example is miR-210, in which its expression level is strongly induced by hypoxia (Ivan and 
Huang, 2014). This miRNA can shield tumor cells from apoptosis during hypoxia by 
targeting the caspase-8 associated protein-2 (CASP8AP2) and the BNIP3 (Kim et al., 2009; 
Wang et al., 2013), and promote angiogenesis by targeting the EFNA3 (Fasanaro et al., 2008). 
Moreover, miR-210 is also induced by pro-inflammatory signals, which targets the NF-κB1 
that suppresses Toll-like receptor 4 mediated pro-inflammatory cytokines (Qi et al., 2012).  
 
1.4.3 miRNAs in virus-related cancers 
In MCC, a miRNA profiling study performed by our group identified a list of miRNAs 
associated with MCPyV status, metastasis stage and clinical outcome (Xie et al., 2014). 
However, the functional evidence of miRNAs in MCC tumorigenesis is limited. To date, only 
a few miRNAs have been functionally characterized in MCC. miR-203 can inhibit cell 
growth and survivin expression in MCPyV- MCC cells (Xie et al., 2014). On the other hand, 
miR-375 was found to suppress neuroendocrine differentiation by targeting multiple Notch 
pathway genes (Abraham et al., 2016) and regulate cell growth via suppression of LDHB 
(Kumar et al., 2018). In Paper II, we demonstrate that miR-375, miR-30a-3p and miR-30a-5p 
can suppress multiple autophagy genes, including ATG7, SQSTM1 and BECN1, leading to 
autophagy suppression. Importantly, miR-375 is also the most abundant miRNA in MCC, 
whose serum level is correlated with tumor burden (Fan et al., 2018), suggesting its potential 
utility as biomarker for disease surveillance. 
Involvement of miRNAs in other virus-related cancer has also been reported. A detailed 
miRNA regulation system has been characterized in hepatitis B or C virus-associated liver 
cancer (Wang et al., 2012). Several miRNAs can regulate viral gene expression level and 
oncogenic signaling in HBV- and HCV-related HCC. For example, miR-122 can bind HCV 
RNA and promote HCV translation and replication. On the other hand, miR-20a and miR-92a 
from the mir-17~92 cluster can bind HBV RNAs and suppress their expressions and viral 
replication (Jung et al., 2013). miR-224 is upregulated in HCC through NF-κB pathways 
(Scisciani et al., 2012) and promotes cell growth, migration, invasion and tumor development 
(Lan et al., 2014; Li et al., 2010; Wang et al., 2008; Zhang et al., 2013). miR-199a/b-3p is 
consistently down-regulated in HCC, which suppresses tumor growth by targeting the 
PAK4/RAF/MEK/ERK signaling (Hou et al., 2011). 
HPV is known to play important role in cervical cancer development. HPV16 and 18, the 
two most common HPV strains that promotes cervical carcinogenesis, can regulate cellular 




shown to suppress miR-34a, miR-23b and miR-145 through destabilization of p53 (Shi et al., 
2012; Wang et al., 2009; Yeung et al., 2011). E7 can induce miR-15b through E2F-mediated 
transcription, resulting from inhibition of Rb-E2F interaction (Myklebust et al., 2011b). 
Additionally, E7 also increases miR-27b expression, which promotes cell growth and 
suppresses apoptosis via polo-like kinase 2  (PLK2) in cervical cancer (Liu, F. et al., 2016; 
Myklebust et al., 2011a). 
These observations highlight the interplay between viral oncoproteins and miRNA 
regulation. Further investigations are still needed to characterize the detailed regulatory 
network of these miRNAs in specific tumor types. 
 
1.4.4 Virus-encoded miRNAs 
Besides cellular miRNAs, some viruses can also encode miRNAs by harnessing host miRNA 
processing machinery. The first evidence of virus-encoded miRNAs was discovered in EBV-
infected cells (Pfeffer et al., 2004). These EBV-encoded miRNAs can affect cell growth, 
apoptosis, metastasis, immune checkpoint, cytokine expression and signal transduction (Cai 
et al., 2015; Cristino et al., 2019; Lyu et al., 2018; Ma et al., 2016; Wang et al., 2019). 
Subsequently, many more miRNAs were found in other herpesviruses, including Kaposi 
sarcoma-associated virus, mouse gammaherpesvirus 68 and human cytomegalovirus (Pfeffer 
et al., 2005). Besides herpesvirus family, several other virus families, including polyomavirus, 
ascovirus, baculovirus and adenovirus, have also been reported to encode miRNAs 
(Grundhoff and Sullivan, 2011). To date, a total of 530 mature miRNAs from 34 different 
viruses are annotated in the miRBase database (release 22.1, October 2018). Their proposed 
function covers viral infection, viral replication, host apoptosis and transformation. MCPyV 
genome consists of a miRNA gene called mcv-miR-M1 (also known as mcpv-mir-P1). This 
miRNA complementarily interacts with the viral LT sequence and controls its expression 
level (Seo et al., 2009). Additionally, this MCPyV miRNA can also suppress host immune 
response by targeting the SP100 innate immunity gene (Akhbari et al., 2018). 
 
1.5 THE PATHOGENESIS OF C-KIT 
 c-KIT is a type III RTK, which was firstly described by Yarden and colleagues in 1987 
(Yarden et al., 1987). This gene is the cellular homolog of the v-KIT oncogene of Hardy-
Zuckerman 4 feline sarcoma virus (Besmer et al., 1986). Later, stem cell factor (SCF) was 
identified as the ligand of c-KIT (Zsebo et al., 1990). Upon ligand binding, c-KIT undergoes 
auto-phosphorylation and activates several downstream signaling pathways (Lennartsson and 
Ronnstrand, 2012). c-KIT is normally expressed in hematopoietic stem cells, germ cells, mast 
cell, melanoblast and interstitial cells of Cajal (Ikuta and Weissman, 1992; Matsui et al., 
1990; Tsai et al., 1991). Its downstream signaling pathways affect cell death, proliferation 




different cancer types; the most well-known types are mast cell leukemia and gastrointestinal 
stromal tumor (GIST) (Lennartsson and Ronnstrand, 2012). 
 
1.5.1 Molecular structure, post-translational modifications and activation of 
c-KIT 
As a typical RTK, the protein structure of c-KIT includes an extracellular domain, a 
transmembrane domain, a juxtamembrane domain and an intracellular domain (Figure 6). 
The extracellular domain is consisted of five IgG-like motifs: the beginning three in the N-
terminus accounts for SCF ligand binding, while the latter two helps the receptor 
dimerization. The SCF always performs as a dimer in order to induce c-KIT dimerization and 
activation. Once the c-KIT homodimeric status is initiated and stabilized by SCF, two 
tyrosine residues (Tyr568 and 570) in the juxtamembrane domain will be phosphorylated, 
continued by multiple phosphorylation modifications in the two kinase domains located in the 
intracellular region (including Tyr at 703, 719, 721, 730, 747 and 900) and the C-terminus 
(Tyr936) (Lennartsson and Ronnstrand, 2012; Serve et al., 1994). 
 
Figure 6. The protein structure and signaling pathways of c-KIT. The c-KIT protein 
consists of extracellular, transmembrane, juxtamembrane and intracellular regions. Upon 
binding with stem cell factor (SCF), multiple tyrosine residues (Y) of c-KIT are 






The native c-KIT is a protein with a molecular weight of about 100 kDa. After synthesis, 
multiple glycosylation modifications occur in the ER and Golgi, in which glycosylations are 
added in the extracellular domain sites to form a high mannose form (120 kDa) and full 
complex glycosylated form (145 kDa) (Majumder et al., 1988; Qiu et al., 1988; Yarden et al., 
1987). The complex glycosylated c-KIT is then transported to the PM for activation by its 
ligand. Upon binding of the SCF, the c-KIT is phosphorylated at multiple sites of tyrosine 
and/or serine residues, which can activate several signaling pathways, such as PI3K-AKT-
mTOR, RAS-MAPK and JAK-STAT (Figure 6)(Blume-Jensen et al., 1994; Growney et al., 
2005). After activation, the c-KIT is ubiquitinated for degradation by the endocytic pathway 
(Masson et al., 2006; Sun et al., 2007). 
 
1.5.2 c-KIT in cancer 
c-KIT activation and overexpression are involved in different cancer types, including GIST, 
SCLC, acute myeloid leukemia, testicular seminoma, melanoma and MCC (Lennartsson and 
Ronnstrand, 2012). GIST is one of the most studied tumor types for c-KIT oncogenic 
functions. About 85% of GISTs harbor c-KIT mutations (Corless et al., 2004). These 
mutations can occur in the transmembrane, juxtamembrane and kinase domains of c-KIT, 
which lead to ligand-independent activation (Hirota et al., 1998; Nishida et al., 1998). This 
activates several signaling pathways, including PI3K-AKT, JAK-STAT, RAS-RAF-MAPK 
and PLC-γ, for promoting tumor growth and apoptosis resistance (Ali and Ali, 2007; Bosbach 
et al., 2017). 
RTK inhibitors can be used to attenuate the activation of downstream signaling of the 
RTK and inhibit tumor growth. Imatinib mesylate is an example of RTK inhibitor that blocks 
certain RTKs, including c-KIT, by binding in the ATP-binding site that blocks substrate 
phosphorylation (Demetri et al., 2002; Tuveson et al., 2001; Wang et al., 2000). The 
inhibition of c-KIT activation by imatinb can induce c-KIT internalization for degradation 
(D'Allard et al., 2013). 
In normal cells, after ligand binding, c-KIT is rapidly internalized by endocytosis for 
recycling or lysosomal degradation. However, several studies indicate that mutated c-KIT 
proteins in GIST and mast cell leukemia are localized in specific organelles for oncogenic 
activities (Obata et al., 2017; Obata et al., 2014; Tabone-Eglinger et al., 2008). Interestingly, 
c-KIT can have different oncogenic signaling in different subcellular compartments. In mast 
cell leukemia, c-KIT proteins are accumulated in both ER and endolysosome. The immature 
c-KIT located in the ER activates STAT5 to promote proliferation, while the mature 
phosphorylated c-KIT in the endolysosome interacts with AKT-p85 that favors tumor cell 
survival (Obata et al., 2014). In GIST, the mutant c-KIT forms a paranuclear dot-like 
aggregation in the Golgi and activates STAT5, PI3K-AKT and ERK pathways to support 




In MCC, we also observed frequent c-KIT paranuclear dot staining in MCPyV+ MCC. 
Unlike GIST and mast cell leukemia, no activating mutation of c-KIT has been found in 
MCC (Waltari et al., 2011). In Paper III, we show that MCPyV LT oncoprotein promotes c-
KIT retention in the late endosomes via its Vam6p interaction and c-KIT binds to BECN1 








2 AIMS OF THE THESIS 
The general aim of this thesis was to demonstrate how members of the protein degradation 
system are regulated in two different types of cancer, i.e. testicular germ cell tumor (TGCT) 
and Merkel cell carcinoma (MCC). The specific aims were to: 
 
• Elucidate the functional role of miR-223-3p and its functional target in TGCT (Paper 
I) 
 
• Characterize the functional role of the MCPyV-associated miR-375, miR-30a-3p and 
miR-30a-5p and their  targets involved in MCC development (Paper II) 
 
• Characterize the c-KIT expression pattern and determine its possible functional 
relationship with MCPyV T-antigens in MCC (Paper III) 
 
• Elucidate the mechanism of  paranuclear CK20 aggregation formation in MCC and 






3 MATERIALS AND METHODS 
3.1  CLINICAL SAMPLES 
3.1.1 Testicular germ cell tumors and normal testes 
Fifteen testicular germ cell tumors (TGCTs) and five normal testes (NT) were provided by 
the Cooperative Human Tissue Network, which is funded by the National Cancer Institute, 
USA. These samples were used in Paper I. 
3.1.2 MCC tumor samples 
Two cohorts were included in this thesis. The Karolinska cohort consists of 45 formalin-fixed 
paraffin-embedded (FFPE) MCC tumor samples collected at Karolinska University Hospital 
or Stockholm South General Hospital. The Helsinki cohort includes tissue microarray (TMA) 
slides containing 435 FFPE MCC tumors provided by Helsinki University Hospital. The 
clinical information of the patients has been described in previous studies (Kumar et al., 
2020; Sihto et al., 2009, 2011; Xie et al., 2014). The Karolinska cohort was used in Papers II 
and III, and the Helsinki cohort was used in Papers III and IV. 
3.2 ESTABLISHED CELL LINES AND MCC PRIMARY CULTURE 
Ten human established cell lines and one MCC primary culture (ME27) were included in this 
thesis work, which are listed in Table 3. 
 
The authenticity of the cell lines has been verified by short tandem repeat (STR) genotyping, 
as shown in Table 4. 
Name Description MCPyV 
status
Source Paper
TCam-2 TGCT n.d. Kindly provided by Dr. Leendert Looijenga 
(Erasmus MC-University, Netherlands)
I
2102Ep TGCT n.d. Kindly provided by Dr. Peter Andrews (University 
of Sheffield, UK)
I
MCC13 MCC negative Cell Bank Australia, Westmead, NSW, Australia II, III, IV
MCC14/2 MCC negative Cell Bank Australia, Westmead, NSW, Australia II, III, IV
MCC26 MCC negative Cell Bank Australia, Westmead, NSW, Australia II, III, IV
WaGa MCC positive Kindly provided by Dr. JC Becker (Medical 
University of Graz, Austria)
II, III, IV
MKL-1 MCC positive Kindly provided by Dr. NL Krett (Northwestern 
University, IL, USA)
II, III, IV
MKL-2 MCC positive Kindly provided by Dr. Roland Houben (University 
of Würzburg, Germany)
II, III, IV
ME27 MCC positive Shi H et al., Unpublished II, III, IV
GIST882 Gastrointestinal 
stromal tumor
n.d. Kindly provided by Dr. JA Fletcher (Brigham and 





n.d. Originally purchased from American Type Culture 
ollection and kindly provided by Dr. Yingbo Lin 
(Karolinska Institutet, Sweden)
III, IV
Table 3. Human established cell lines and primary culture used in this thesis





3.3 DATA FROM PREVIOUS PUBLISHED STUDY AND PUBLIC DATABASES  
We extracted miR-223-3p and miR-16 expressions from the global TaqMan miRNA profiling 
data published in (Gillis et al., 2007), consisting of 49 TGCTs and three NTs. The miR-223-
3p levels were normalized to miR-16. 
For comparison of FBXW7 mRNA levels between TGCTs and NTs, we extracted the 
microarray gene expression data deposited at the National Center for Biotechnology 
Information Gene Expression Omnibus (GEO accession no. GSE3218), which consists of 
101 TGCTs and five NTs. 
For correlation analysis between FBXW7 mRNA and miR-223-3p, their expression data 
were extracted from The Cancer Genome Atlas. The details are described in Paper I. 
 
3.4 RNA EXTRACTION AND REVERSE TRANSCRIPTION-QUANTITATIVE 
POLYMERASE CHAIN REACTION (RT-QPCR) 
Total RNAs for both cell cultures and tissue samples were prepared using mirVANATM 
miRNA Isolation Kit (Ambion, Thermo Fisher Scientific, CA, USA). The procedure includes 
the classical acid phenol and chloroform extraction, followed by solid phase column RNA 
immobilization, purification and elution. RNA purity and concentration was measured by 
NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, DE, USA). 
RT-qPCR assay is based on PCR reaction, which is commonly used to quantify RNA 
expression levels by measuring the amount of fluorescence signals released during PCR 
amplifications in real-time. The first step needs to convert the RNA into single-stranded 
complementary DNA (cDNA). The qPCR part contains two widely used methods: SYBR-
green and TaqMan assays. SYBR-green assay uses the SYBR green dye, which only binds to 
double-stranded DNA formed during PCR step and this dye only give fluorescence signals 
Table 4. Short tandem repeat profiles of the established human cell lines involved in this thesis 
Locus TCam2 2102Ep WaGa MKL-1 MKL-2 MCC13 MCC14/2 MCC26 GIST882 
D8S1179 14, 17 14, 15 10, 13 10, 10 11, 13 13, 14 10, 14 8, 10 12, 12 
D21S11 30, 30 28, 29 28, 30 30, 30 31.2, 31.2 30, 31 29, 32.2 31, 32.2 29, 31.2 
D7S820 8, 11 7, 7 10, 10 8, 11 10, 13 10, 10 8, 10 8, 9 10, 15 
CSF1PO 9, 11 11, 12 12, 12 11, 12 10, 12 12, 12 10, 11 10, 11 11, 11 
D3S1358  16, 17 16, 16 14, 14 16, 16 17, 17 16, 18 16, 16 17, 17 15, 15 
THO1  6, 9 9, 9.3 9.3, 9.3 9, 9.3 7, 8 7, 9.3 6, 9.3 9.3, 9.3 9, 9 
D13S317 8, 12 8, 8 8, 13 8, 11 12, 13 12, 12 13, 13 13, 14 12, 12 
D16S539  9, 9 11, 12 11, 12 10, 12 10, 12 9, 11 13, 13  11, 13 11, 11 
D2S1338 23, 23 17, 20 20, 23 17, 17 17, 23 19, 20 19, 19 23, 26 18, 26 
D19S433  15, 15 13, 14 14, 16 14.2, 15.2 13.2, 14 15, 15 12, 14  16, 16 13, 15 
vWA  18, 19 16, 17, 18 16, 17 16, 18 16, 17 17, 17 17, 18 16, 18 16, 17 
TPOX  9, 9 8, 11 8, 11 8, 8 8, 11 8, 8 8, 8  8, 8 11, 11 
D18S51  13, 13 15, 15 10, 13 12, 18 14, 17 16, 17 15, 17 15, 18 14, 14 
AMEL   X, Y  X, Y  X, Y X, Y X, Y X, X X, X X, X X, Y 
D5S818  11, 12 11, 11 12, 12 11, 12 12, 14 9, 12 13, 13 12, 12 12, 12 




while binding. This character offers the possibility to detect the amplified product at each 
round of PCR. SYBR green assay was used to evaluate mRNA expression level of MCPyV 
T-antigens in Paper II.  
The miRNA reverse transcription primers contain a special target-specific stem-loop 
design, which provides highly specific binding only towards the chosen mature miRNA 
sequence for cDNA synthesis. Besides, the TaqMan probe contains a fluorescence reporter 
dye at the 5’ end and a quencher at the 3’ end. When the probe is cleaved during PCR 
extension step, it releases the fluorescence signals. TaqMan assay can also be used for mRNA 
analysis, and it provides better specificity than the SYBR green assay by designing a probe 
spanning the exon-exon junction of the target mRNA. TaqMan assays were used to detect 
miR-223-3p in Paper I, and miR-375, miR-30a-3p, miR-30a-5p, miR-125a-3p, miR-16, pri-
mir-375, pri-mir-30a, 18S rRNA and RUB6B in Paper II. 
 
3.5 PLASMIDS, MIRNA INHIBITORS, MIRNA MIMICS, SHRNAS AND SIRNAS 
3.5.1 Plasmids and expression vectors  
Plasmids are small circular extra-chromosomal DNA molecules, which can independently 
replicate in bacterial host cells. They have been widely used as an expression vector to 
introduce gene(s) of interest in vitro. Four types of plasmid expression vectors have been 
used in this thesis: protein expression, short-hairpin RNA (shRNA), miRNA sponge, miRNA 
expression and luciferase reporters. 
Protein expression plasmid provides the DNA template for transcription and translation 
by the host machineries that lead to expression the transgene of interest. This type of plasmid 
has been applied to express FBXW7 in Paper I.  MCPyV sT, full-length and truncated LT 
(sTco, LTco and LT339, respectively), D44N point mutant of LT (LTD44N), mRFP-GFP-LC3 
reporter in Paper II; wild-type and W209A point-mutant of truncated LT (LT339 and 
LT339W209A, respectively), wild-type c-KIT, FLAG-tagged full-length and deletion mutants of 
BECN1 in Paper III; wild-type and truncated MCPyV T-antigens and mCherry-tagged 
Dynamitin in Paper IV. 
miRNA sponge is a vector that can express RNAs containing multiple miRNA binding 
sites, which sequesters the targeting miRNA from its cellular targets and suppresses the 
miRNA function. The design of miRNA sponge vector for targeting miR-375, miR-30a-3p 
and miR-30a-5p are described in Paper II. 
Luciferase reporter is widely used to monitor gene expression based on the 
bioluminescence of the luciferase activity generated from the luciferase gene that is coupled 
to the gene of interest. We applied the pmirGLO luciferase reporter, which contains miRNA 




mature miRNA at the 3’ end of the luciferase gene for validation of miRNA targeting sites 
and the efficiency of miRNA sponge in Paper II. 
Short hairpin RNA (shRNA) is used to express single-stranded RNAs with a loop 
structure. Once the shRNA has been transcribed in the host cell, it is processed by Dicer in 
cytosol to produce small interfering RNA (siRNA) duplexes. One strand of the siRNAs is 
then loaded into RISC for silencing the target gene. Several shRNAs were generated and 
applied in this thesis work, including: shTA, which targets the common exon 1 of both LT 
and sT; shsTA, which targets the unique sequence of sT in exon 2 (Papers II and III); 
shKIT, which targets the c-KIT (Paper III); shBAG, which targets the BAG3 (Paper IV). 
All plasmids used in this thesis are listed in Table 5. 
 
 
Table 5. All plasmids used in the thesis
Plasmid Source Identifier* Paper
pcCMV-Myc-FBXW7 Rajagopalan et al., 2004 RRID_Addgene_16652 I
pcDNA3-U6M2-miR-30a This thesis N/A II
pcDNA3-U6M2-miR-30a-3p This thesis N/A II
pcDNA3-U6M2-miR-30a-5p This thesis N/A II
pcDNA3-miR-375sp This thesis N/A II
pcDNA3-miR-30a-3psp This thesis N/A II
pcDNA3-miR-30a-5psp This thesis N/A II
pmirGLO-ATG7wt This thesis N/A II
pmirGLO-ATG7mut This thesis N/A II
pmirGLO-BECN1wt This thesis N/A II
pmirGLO-BECN1mut1 This thesis N/A II
pmirGLO-BECN1mut2 This thesis N/A II
pmirGLO-SQSTM1wt This thesis N/A II
pmirGLO-SQSTM1mut This thesis N/A II
mRFP-EGFP-LC3 (or ptfLC3) Kimura et al., 2007 RRID_Addgene_21074 II
pcDNA6.MCV.LTco.D44N Kwun et al., 2009 N/A II
pcDNA6.MCV.LTco Shuda et al., 2011 RRID:Addgene_40200 II-IV
pcDNA6.MCV.LT339 Shuda et al., 2008 RRID:Addgene_28193 II-IV
pcDNA6.MCV.sTco Shuda et al., 2011 RRID:Addgene_40201 II-IV
pcDNA3-U6M2-shTA Xie et al., 2014 N/A II-IV
pcDNA3-U6M2-shsTA This thesis N/A II-IV
pcDNA3-c-KIT-WT Agarwal et al., 2013 N/A III
pcDNA4.Beclin1 (FL).3xFLAG Sun et al., 2008 RRID:Addgene_24388 III
pcDNA4.Beclin1 1-150.3xFLAG Sun et al., 2008 RRID:Addgene_24389 III
pcDNA4.Beclin1 151-241.3xFLAG Sun et al., 2008 RRID:Addgene_24390 III
pcDNA4.Beclin1 243-450.3xFLAG Sun et al., 2008 RRID:Addgene_24392 III
pcDNA4.Beclin1 Δ151-241.3xFLAG Sun et al., 2008 RRID:Addgene_24393 III
pcDNA3-U6M2-shKIT This thesis N/A III
pcDNA6.MCV.LT339.W209A This thesis N/A III, IV
pcDNA3-U6M2-shBAG3 This thesis N/A IV
mCherry-Dynamitin Shrum et al., 2009 N/A IV
mCherry-C2 N/A RRID:Addgene_54563 IV





3.5.2 miRNA inhibitors, miRNA mimics and siRNAs 
miRNA inhibitors are chemically modified single-stranded RNAs that bind and attenuate the 
function of specific endogenous miRNAs. miRNA mimics are chemically modified double-
stranded RNAs that produce mature miRNA of interest, which can be loaded into RISC 
complex and execute similar function as the corresponding endogenous miRNA. The 
negative controls are RNA molecules with similar chemical modification as the miRNA 
inhibitors or mimics but with non-targeting random sequence. In Paper I, we applied miRNA 
mimic (Pre-miR-223), miRNA inhibitor (Anti-miR-223) and their respective controls (Pre-
miR-NC and Anti-miR-NC) to evaluate the effect of miR-223-3p regulation on FBXW7 
expression and functions. 
siRNAs are chemically modified synthetic small RNA oligonucleotides mimicking the 
endogenous siRNA duplexes that can be loaded directly to the RISC for silencing target 




Transfection is a molecular technique that introduces the exogenous nucleic acid into the 
eukaryotic cells for regulation of gene expression in vitro. Two types of transfection methods 
have been used in this thesis, which are briefly described below: 
 
3.6.1 Lipid-based transfection 
This method is based on the lipid-based particles that can pack the nucleic acid in the 
complex, which fuse with the cellular membrane and deliver the nucleic acid into the cells. 
Examples of lipid-based transfection reagents are: siPORT-NeoFX and Lipofectamine 2000 
in Paper I, Lipofectamine RNAiMAX in Paper II, and Lipofectamine LTX in Papers II-IV. 
 
3.6.2 Electroporation 
Electroporation is a method that directly uses high voltage pulse to create transient opening 
pores in both plasma and nuclear membranes, allowing the nucleic acid to enter targeted 
cells. This method is specifically useful for transfection of large DNA molecules or cells with 
low transfection efficiency such as primary cell cultures, non-dividing cells and stem cells. 
We used the Ingenio electroporation system (Mirus Bio, Madison, WI, USA) and the 





3.7 WESTERN BLOT 
Western blot is a well-established technique to detect and quantify protein of interest. The 
first step is to prepare protein lysate from cells or tissues using lysis buffer or homogenization 
extraction. Subsequently, the sample lysates will be loaded into a SDS polyacrylamide gel for 
protein separation by electrophoresis. Proteins will be separated by velocity according to their 
molecular weights and charges. The separated proteins are then transferred to a membrane 
(nitrocellulose or polyvinylidene difluoride), where proteins can be detected using specific 




Immunostaining is a method to detect the expression and subcellular localization of specific 
protein in a cell or tissue. This method first requires the antigen (i.e. proteins of interest) 
exposure treatment from the biomaterial barriers, such as cellular membrane and adjacent 
tissues, followed by binding with specific primary and secondary antibodies sequentially. The 
secondary antibody can be conjugated with an enzyme (e.g. alkaline phosphatase and 
horseradish peroxidase) or a fluorophore. For the secondary antibody conjugated with an 
enzyme, a chromogen substrate is needed to generate color precipitate for visualization by the 
enzymatic activities, while the fluorescence signals can be visualized directly using the 
fluorescence microscopy. The immunostaining assays used in this thesis includes 
immunohistochemistry (IHC) for tissue samples and immunofluorescence (IF) for cell lines. 
IHC with chromogen substrate was used for ATG7 and p62 detection in Paper II, while IHC 
with double flourescence was used for detection of c-KIT and LT in Paper III, and CK20 
and LT in Paper IV. IF with chromogen substrate was used to detect CK20 or MNF116 in 
MCC cell lines in Paper IV, while the fluorescence detection was used to detect the co-
immunostaining of MCPyV LT and autophagy reporter mRFP-GFP-LC3 in Paper II, c-KIT, 
MCPyV T-antigens, GOLGB1, 58K, EEA1, CD63, LAMP1, BECN1, MNF116 and Rab11a 
in Paper III, CK20, MCPyV T-antigens, MNF116, BAG3, HDAC6, Ub(48K), γ-tubulin, and 
Vimentin in Paper IV. Cell nuclei were counter-stained with 4′,6-diamidino-2-phenylindole 
(DAPI) due to its strong binding to adenine-thymine region in DNA, which could be 
visualized by fluorescence microscopy (Papers II-IV). 
 
3.9 CO-LOCALIZATION AND CO-IMMUNOPRECIPITATION ASSAYS 
Protein-protein interactions can be detected by co-localization analyses of two different 
fluorescently labeled proteins and co-immunoprecipitations. Additionally, 
immunoprecipitation can also be used to pull down vesicles using organelle-specific 





3.9.1 Immunofluorescence based co-localization assay 
For co-localization analysis, the two proteins are detected by different host-specific primary 
antibodies and fluorescent-tagged secondary antibodies using IF. Pearson’s correlation 
coefficient will be calculated for the co-localization pixels between the two fluorescence 
channels, which provides a quantitative measurement of their co-localization (Costes et al., 
2004). During the image acquisition, the optimal optical setup for different fluorescence 
signals needs to be considered in order to get a constant point spread function (PSF) for 
correction of pixel intensities. PSF is calculated by laser wavelength lambda / (2 * N.A.), 
N.A. = numerical aperture value of the lens used for detection. In Paper III, Pearson’s 
correlation coefficient was calculated using the Coloc 2 plugin of ImageJ software (version 




Co-immunoprecipitation (Co-IP) is a widely used approach to capture the target protein and 
its associated proteins in a protein lysate, based on antibody recognition and immobilization. 
Generally, specific antibody is used to capture the protein of interest and other proteins that 
bound to the target protein in protein lysates, in which the antibody-antigen complex is then 
immobilized on beads, and eventually pulled out from the total lysate. The isolated protein 
complexes are analyzed by protein analysis methods, e.g. western blot. Co-IP assay was used 
to analyze the interaction between c-KIT and BECN1 as well as BECN1-associated 
complexes in Paper III, and between LT and Vam6p interaction in Paper IV. 
 
3.9.3 Vesicle immunoprecipitation 
Based on the same principle as co-IP, cellular vesicles can be pulled down for analysis. The 
difference is the cell lysis procedures, which need to break down the plasma membrane but 
keep the intact of vesicle compartment. This is normally achieved by using hypotonic buffer 
that swells and breaks the cell membrane, but not the cellular organelles. The vesicles can be 
enriched by immunoprecipitation using organelle-specific antibody and the content of the 
vesicles can be detected by western blotting. Vesicle IP has been used to isolate the late 
endosome and lysosome/endolysosome vesicles using anti-CD63 and anti-LAMP1, 
respectively, in Paper III. 
 
3.10 AUTOPHAGY ASSAYS 
Multiple autophagy assays are recommended to evaluate the effect on autophagy, due to its 




3.10.1  Transmission electron microscopy 
Transmission electron microscopy (TEM) is a direct method to evaluate the morphology of 
autophagosomes (organelle with double membrane, which is separated by a bright lumen) 
and autolysosomes (single membrane structure containing partially degraded or electron 
dense material due to acidic environment). TEM was applied for evaluating the effect of 
MCPyV T-antigens and miRNAs on autophagosomes and autolysosomes (Paper II). 
Although this method is useful, it has limitation for quantification. 
 
3.10.2 Western blot detection of LC3-II 
LC3 (also known as ATG8) is a protein that has both non-lipidated (LC3-I) and lipidated 
(LC3-II) forms. The LC3-I form is found in the cytoplasm, while the membrane-bound LC3-
II is converted from LC3-I and that is involved in membrane closure of autophagosome. 
After fusion with lysosome, LC3-II is degraded in autolysosomes. Due to this dynamic 
process, it is necessary to quantify the amount of LC3-II in the presence or absence of 
lysosome inhibitor treatment (e.g. Bafilomycin A1) in order to distinguish autophagy flux or 
autophagy formation. This method was used in Papers II and III to evaluate the effect of 
MCPyV T-antigenes, miRNA and c-KIT silencing on autophagy. 
 
3.10.3 mRFP-GFP-LC3 autophagy tandem reporter assay 
The mRFP-GFP-LC3 reporter is a very useful assay to quantify the number of 
autophagosomes and autolysosomes based on the fluorescence puncta. The principle of this 
assay is based on the acidic environment in autolysosomes that quenches GFP signal, but not 
mRFP. Therefore the red (mRFP only) puncta represent the autolysosome, while the 
autophagosome is represented by yellow (mRFP+GFP) puncta. This reporter was used in 
Paper II. 
 
3.11 FUNCTIONAL ASSAYS 
3.11.1 Cell viability/proliferation assays 
Three different cell growth assays have been applied in this thesis: trypan blue exclusion, 
WST-1 and 5-ethynyl-2'-deoxyuridine (EdU) assays. 
Trypan blue is a dye that can quickly check the percentage of live cells from the sample 
using bright field microscopy or automatic cell counting. The principle is that membrane-
intact alive cells will not be stained with the dye, but the dead cell will be stained due to loss 




WST-1 assay is based on the cleavage of tetrazolium salt to color formazan by the 
dehydrogenase enzyme from mitochondria of live cells. The color formazan can be measured 
at 440 nm, and the intensity is directly proportional to mitochondria activity from live cells, 
therefore it corresponds to cell viability or growth. WST-1 assay was used to assess cell 
growth in Papers I and II.  
Cell proliferation requires the replication of genomic DNA, therefore quantification of 
newly synthesized DNA is a direct method for measuring cell proliferation. EdU is a 
thymidine analog, which is incorporated into DNA during DNA synthesis. The EdU contains 
the alkyne and azide-Alexa Fluor dye, which can be used to catalyze a chemical reaction to 
incorporate a fluorescence dye. The fluorescently labeled live cells can be assessed by flow 
cytometry. This assay was used to evaluate the effect of miR-223-3p on cell proliferation in 
TCGT cells (Paper I). 
 
3.11.2 Cell apoptosis assays 
Apoptosis is a term describing programmed cell death. It is considered as vital process for 
homeostasis maintenance, embryonic development and normal function of immune system. 
Abnormal apoptosis is often linked to pathogenic conditions, such as carcinogenesis. Several 
experimental methods can be used to evaluate apoptosis, which are normally divided into two 
groups: morphology of apoptotic cells and apoptotic marker. 
Morphology is based on the membrane integrity of apoptotic cells. Annexin V can bind 
to phosphatidylserine (PS). In healthy cells, PS stays in the inner membrane leaflet to 
maintain the cell membrane structure. When apoptosis is initiated, the cellular membrane is 
still intact, therefore the permeable dye (such as trypan blue and propidium iodide) cannot 
enter into the cells. However the membrane asymmetry is damaged and PS is translocated to 
the external side, where it is exposed for Annexin V binding. Thus, Annexin V, combined 
with propidium iodide, can detect early and late apoptosis, which was used in Papers I and 
II. 
The poly (ADP-ribose) polymerase-1 (PARP-1) is a cleavable substrate by the 
proteolytic function of cellular caspases, including caspase 3 and caspase 7. Besides, PARP 
plays important role in DNA repair to preserve cell viability. During apoptosis, the 116 kDa 
PARP is cleaved at Asp214-Gly215 into two subunits (89 kDa and 24 kDa) by caspase 3 that 
prevents DNA repair. The amount of cleaved PARP can be utilized as an apoptosis marker. 
This assay was used in Papers I and III. 
 
3.12 STATISTICAL ANALYSIS METHODS 
All statistical methods in this thesis were performed by MS Office Excel 2007, SPSS 22.0 or 




two continuous factors (FBXW7 mRNA v.s. miR-223-3p) in Paper I. Mann-Whitney U-test 
was used to compare miR-223-3p or FBXW7 mRNA in TGCT v.s. NT (Paper I), c-KIT 
staining dot pattern between MCPyV+ and MCPyV- MCC groups (Paper III), CK20 
staining dot pattern between MCPyV+ and MCPyV- MCC groups (Paper IV). Student 
paired t-test was used to compare two experimental conditions in Papers I-IV. One-way 
ANOVA with post hoc Tukey test was used to compare multiple experimental conditions 
(Paper II). One-way ANOVA with post hoc Dunnett test was used to compare multiple 
experiment conditions v.s. a control (Papers III and IV). Two-way ANOVA with post hoc 
Dunnett test was used to detect interactions with two affecting factors in Paper III. χ2 or 
Fisher’s exact test was used to evaluate association of ATG7 or p62 protein levels with virus 
status in MCC tumors (Paper II), c-KIT dot/membrane staining pattern between MCPyV+ 
and MCPyV- MCC samples (Paper III) and CK20 dot/diffuse-cytoplasmic staining pattern 
between MCPyV+ and MCPyV- MCC groups (Paper IV). All analyses were characterized 





4 RESULTS AND DISCUSSIONS  
4.1 MIR-223-3P REGULATES CELL GROWTH AND APOPTOSIS VIA FBXW7 
SUGGESTING AN ONCOGENIC ROLE IN HUMAN TESTICULAR GERM 
CELL TUMORS (PAPER I) 
As previously published by our group, a subset of miRNAs with dysregulated expression 
level has been identified in testicular germ cell tumors (TGCTs), by small RNA sequencing 
analysis (Ozata et al., 2017). miR-223-3p is one of the up-regulated miRNAs in TGCTs, but 
its functional role in TGCT development was still unknown. Therefore, this study was 
conducted to explore the functional role of miR-223-3p in TGCTs. 
 
4.1.1 miR-223-3p regulates FBXW7 protein expression in TGCT 
To further confirm the upregulation of miR-223-3p in TGCTs, we re-analyzed the miRNA 
profiling data from the study of Gillis et al., which showed increased expression of miR-223-
3p in TGCTs (Gillis et al., 2007). 
FBXW7 has been verified as a direct target of miR-223-3p in different cancer types 
(Kurashige et al., 2012b; Li, J. et al., 2012; Mavrakis et al., 2011), we therefore evaluated 
FBXW7 protein expression in our cohort and FBXW7 mRNA in microarray gene expression 
data from a public database (GEO GSE3218). We found decreased expression of FBXW7 in 
TGCTs than normal testes (NTs) in both cohorts. Using the TCGA data, we found negative 
correlation between FBXW7 mRNA and miR-223-3p in a series of 101 TGCTs and five NTs.  
To further evaluate whether FBXW7 could be a target of miR-223-3p in TGCT, we 
suppressed (using anti-miR-223) or overexpressed (using pre-miR-223) in TGCT cell lines, 
which resulted in increased or decreased FBXW7 protein levels, respectively, suggesting that 
miR-223-3p negatively regulates FBXW7 in TGCT. 
 
4.1.2 miR-223-3p regulates cell apoptosis and cell growth in TGCT cell lines 
To address the biological consequence of miR-223-3p in TGCT, we modulated miR-223-3p 
expression and evaluated the effect on apoptosis and cell growth. We showed that 
suppression of miR-223-3p increased apoptosis, as evaluated by Annexin V assay and 
detection of cleaved PARP by immunoblotting. On the other hand, overexpression of miR-
223-3p had an opposite effect.  
For cell growth analysis, we applied both EdU and WST-1 assays. Inhibition of miR-
223-3p led to decreased cell growth, while its overexpression promoted cell growth in vitro. 





4.1.3 The miR-223-3p mediated apoptosis and cell growth could be restored 
by ectopic expression of FBXW7 
To further assess whether FBXW7 contributes to the miR-223-3p mediated functional effects, 
we co-transfected pre-miR-223 or pre-miRNA negative control together with full-length 
coding sequence of FBXW7 or empty vector control into TCam-2 cell line. The miR-223-3p 
mediated apoptosis suppression and cell growth promotion were reversed by the ectopic 
expression of FBXW7, suggesting that miR-223-3p controls cell growth and apoptosis 
through FBXW7.  
 
Deregulation of miR-223-3p has been reported in various tumor types. It is known that 
miR-223-3p can function as an oncogene or a tumor suppressor gene in different cellular 
context (Fazi et al., 2007; Li et al., 2011; Petrocca et al., 2008b; Xu et al., 2013). Here, we 
show that miR-223-3p has an oncogenic role in TGCT. Given that most TGCTs are 
responsive to cisplatin treatment and miR-223-3p has been demonstrated to modulate 
cisplatin sensitivity in different cancer types, it is worthy to examine the relationship between 
miR-223-3p expression levels and cisplatin response in TGCT.  
In addition, FBXW7 is an E3 ligase, which is known to function as a tumor suppressor 
by controlling the degradation of multiple oncoproteins involved in cell growth, apoptosis 
and cell cycle, such as c-Myc and Cyclin E (Welcker and Clurman, 2008). Thus, the 
functional phenotypes observed in this study are likely due to accumulation of FBXW7 
substrates. Further investigations are still warranted to elucidate the regulatory network of 
miR-223-FBXW7. 
In conclusion, we demonstrate dysregulation of miR-223-3p and FBXW7 in TGCT. Our 
data suggest an oncogenic role for miR-223-3p, which promotes cell growth and suppress 
apoptosis through suppression of FBXW7. This study provides further insights about the role 





4.2 MERKEL CELL POLYOMAVIRUS ONCOPROTEINS INDUCE MICRORNAS 
THAT SUPPRESS MULTIPLE AUTOPHAGY GENES (PAPER II) 
Our group previously identified a subgroup of miRNAs associated with MCPyV status in 
MCC (Xie et al., 2014). Among the verified deregulated miRNAs, miR-30a-3p, miR-30a-5p 
and miR-375 are overexpressed in MCPyV+ compared to virus-negative MCC tumors. 
Previous studies have reported that miR-375 and miR-30a-5p target ATG7 and BECN1, 
respectively (Chang et al., 2012; Zhu et al., 2009). Therefore, we sought to investigate the 
relationship of these miRNAs with MCPyV and to determine whether these miRNAs could 
regulate autophagy in MCC. 
 
4.2.1 MCPyV T-antigens regulates miRNAs through the viral DnaJ domain 
We first determined whether the MCPyV T-antigens regulate the miRNA levels. We 
designed two short hairpin shRNAs, one targeting the common exon 1 of viral T-antigens 
(shTA) that silences LT and sT, and the other targeting the unique sequence of sT (shsTA) 
that silences sT only. Indeed, we observed reduced expression of miR-375, miR-30a-3p and 
miR-30a-5p upon silencing of LT and sT or sT only. Concordantly, overexpression of 
different T-antigens (sT, full-length LT and truncated LT) induced expressions of all three 
MCPyV-associated miRNAs.  
Upon inhibition of transcription using actinomycin D, we did not observe any effect on 
RNA stability of the primary transcripts for both miR-375 and miR-30a, but the mature 
miRNAs miR-375, miR-30a-3p and miR-30a-5p were decreased in cells with silencing of LT 
and sT or sT only. These results suggest that MCPyV T-antigens regulate miRNAs at post-
transcriptional level. The DnaJ domain is the only common domain between LT and sT, and 
it has been proven to interact with HSC70 (Kwun et al., 2009). Given that HSC70 is linked to 
miRNA processing complex RISC (Iwasaki et al., 2010), we speculated that this domain 
could contribute to miRNA regulation. Indeed, mutation in the DnaJ domain, LTD44N 
abolished the induction of miR-375, miR-30a-3p and miR-30a-5p by LT. These findings 
indicate that the DnaJ domain of MCPyV T-antigens is required for miRNA regulation. 
 
4.2.2 MCPyV T-antigens suppress autophagy in MCC cell lines 
We next investigated whether MCPyV T-antigens modulate autophagy in MCC cell lines. 
Three different autophagy assays were applied to evaluate the autophagy levels, i.e. 
immunoblotting detection of LC3-II, mRFP-GFP-LC3 reporter and transmission electron 
microscopy. Silencing of LT and sT or sT only significantly upregulated LC3-II level, as well 
as increased number of autophagosomes and autolysosomes evaluated by TEM and mRFP-





To further evaluate the association of MCPyV and autophagy suppression in clinical 
samples, we assessed the expression of two key autophagy factors ATG7 and SQSTM1 (also 
known as p62) using immunohistochemistry in our MCC cohort. The staining for both ATG7 
and p62 were significantly lower in MCPyV+ compared to MCPyV- MCC tumors. These 
results provide evidence of autophagy suppression in MCPyV+ MCC. 
 
4.2.3 MCPyV-regulated miRNAs suppress autophagy by targeting multiple 
autophagy genes 
Using both gain- and loss-of-function experiments, we demonstrated that miR-375, miR-
30a-3p and miR-30a-5p regulate autophagy, as evaluated by the three autophagy assays 
mentioned above. We also confirmed miR-375 and miR-30a-5p directly suppresses ATG7 and 
BECN1, respectively, in MCC. In addition, we also identified SQSTM1 and BECN1 are novel 
targets of miR-375 and miR-30a-3p, respectively, in MCC. Their direct interactions were 
validated by luciferase reporter assays. Together, these results suggest that MCPyV 
oncoproteins suppress autophagy through induction of miR-375, miR-30a-3p and miR-30a-5p 
that target multiple autophagy genes. 
 
4.2.4 Autophagy inhibition could rescue Torin-1 induced cytotoxicity in MCC 
cell lines 
Since autophagy can regulate cell death (White, 2015), we hypothesized that suppression of 
autophagy by MCPyV T-antigens could favor MCC viability. We therefore used mTOR 
inhibitor Torin-1 to trigger autophagy in MCPyV+ MCC cells, together with and without 
autophagy inhibitor baf. A1 or pan-caspase inhibitor z-VAD-FMK, to assess the effect on cell 
viability. Using both WST-1 and Annexin V assays, we showed that Torin-1 induced cell 
death and reduced cell viability that could be rescued by the autophagy inhibitor baf. A1, but 
not the pan-caspase inhibitor. 
 
Here, we uncovered a novel role of MCPyV T-antigens in autophagy suppression. As 
described in Section 1.3.3, some tumor viruses can modulate autophagy for transformation 
and tumorigenesis (Ding et al., 2014; Lin et al., 2019; Wileman, 2007). Even though the 
functional roles of autophagy in MCPyV infection and tumorigenesis remain unknown, it is 
tempting to postulate that autophagy evasion may help MCPyV to escape host immunity 
during viral infection and may protect oncoproteins that are degraded by autophagic 
mechanism. Indeed, we show that autophagy can degrade LT (Paper III).  
Besides, autophagy has dual roles in different cancers. Generally, autophagy is regarded 
as pro-survival in tumors, in which the increased autophagic flux is required for tumor cell 




other hand, our data suggest anti-survival role for autophagy in MCPyV+ MCC. In line with 
our study, autophagy suppression has also been reported in other viral related cancers (Ding 
et al., 2014; Lin et al., 2019). These data suggest that autophagy suppression might be 
essential for viral-related cancer. There are two published studies to suggest a link of 
autophagy in MCC development. Shuda et al. demonstrated that sT could activate mTOR and 
its downstream targets 4E-BP1 and S6K (Shuda et al., 2011). mTOR activation can lead to  
autophagy inhibition (Kim and Guan, 2015). Notably, mTOR activation and suppressed 
autophagy were also observed in MCC tumor samples (Lin et al., 2014). Here, we provided 
direct evidence that both sT and truncated LT can suppress autophagy. Interestingly, the full-
length LT did not show consistent suppression effect. This could be explained by the 
carboxyl-terminus of LT containing the helicase domain, which can inhibit cell growth and 
induce DNA damage response (Cheng et al., 2013).  
In summary, we reveal a network for MCPyV T-antigens mediated suppression of 
autophagy through miRNA activities. The viral oncoproteins induce miR-375, miR-30a-3p 
and miR-30a-5p to inhibit the expression of multiple autophagy factors, including SQSTM1, 
BECN1 and ATG7. Autophagy suppression protects MCC cells from Torin-1 cytotoxicity, 





4.3 MERKEL CELL POLYOMAVIRUS ONCOPROTEIN INDUCES 
PARANUCLEAR RETENTION OF C-KIT SUPPRESSING AUTOPHAGY 
THROUGH INTERACTION WITH BECLIN-1 (PAPER III) 
c-KIT (also known as CD117) is a type III receptor tyrosine kinase, which has been validated 
as an oncogene in different cancer types (Lennartsson and Ronnstrand, 2012). In MCC, 
overexpression and activation of c-KIT has been reported (Husein-ElAhmed et al., 2016; 
Krasagakis et al., 2009; Swick et al., 2013; Waltari et al., 2011). Yet, c-KIT activating 
mutations are rare in MCC (Rodig et al., 2012; Swick et al., 2013; Waltari et al., 2011), and 
the association of c-KIT expression level with virus status in MCC is unknown (Brunner et 
al., 2008; Kuwamoto, 2011; Waltari et al., 2011). Here, we describe a molecular mechanism 
how MCPyV oncoprotein blocks lysosomal degradation of c-KIT, leading to its stabilization 
and interaction with BECN1 for autophagy regulation. 
 
4.3.1 The paranuclear c-KIT dot is associated with MCPyV+ MCC and is 
localized in late endosomes 
We first characterized c-KIT expression pattern in MCC using IHC. Unexpectedly, we 
observed that c-KIT has a special paranuclear dot-like pattern in MCPyV+ MCC cell lines 
and tumor samples, while MCPyV- MCC cell lines had low or no expression of c-KIT and 
membranous or cytoplasmic staining pattern of c-KIT were more frequently found in 
MCPyV- MCC tumors.  
The paranuclear c-KIT dot has also been observed in GIST and mast cell leukemia and 
their different subcellular localizations have been shown to execute different oncogenic 
signaling (Obata et al., 2017; Obata et al., 2014). These observations led us to investigate the 
subcellular localization of c-KIT. We applied co-staining of c-KIT together with different 
cellular organelle markers, including Golgi, early endosome, late endosome and 
endolysosome. Co-localization analysis using the Pearson’s correlation coefficients showed 
that c-KIT had strongest co-localization with both late endosome marker CD63 and 
endolysosome marker LAMP1. To distinguish these two compartments, we performed 
vesicle-immunoprecipitation assays with anti-CD63 or anti-LAMP1 in MCPyV+ cells, which 
revealed that c-KIT was mainly localized in late endosomes. Our data indicate that the 
paranuclear retention of c-KIT is associated with MCPyV+ MCC, and c-KIT is aggregated in 
late endosomes. 
 
4.3.2 c-KIT is fully glycosylated and phosphorylated, and it traffics from 
plasma membrane to late endosome via clathrin-dependent 
endocytosis 
In normal cells, c-KIT undergoes a series of modification in ER and Golgi to become fully 
glycosylated form, which is then phosphorylated upon binding to its ligand on the plasma 




MCPyV+ MCC cell lines was digested by PNGase F (which digests complex glycosylation 
form), but not with endo H (which digests the high-mannose N-glycosylation form), 
indicating that the c-KIT is fully glycosylated. To evaluate c-KIT phosphorylation status, we 
chose to analyze phosphorylation at tyrosine 719 residue, which accounts for the c-KIT 
kinase-dependent PI3K-AKT signaling (Hashimoto et al., 2003). We detected pTyr-719 of c-
KIT in all three MCPyV+ MCC cell lines, indicating that c-KIT is activated in MCPyV+ 
MCC.  
We next investigated how c-KIT was transported from plasma membrane to late 
endosomes. Generally, mammalian cells used either clathrin-mediated endocytosis (CME) or 
lipid raft-dependent non-clathrin endocytosis (NCE) to transport RTK for lysosomal 
degradation or recycling (Barbieri et al., 2016). We found that CME inhibition using Pitstop2 
and hypertonic sucrose, but not with NCE inhibitor Filipin, led to accumulation of c-KIT on 
plasma membrane. Furthermore, the possible involvement of c-KIT receptor recycling was 
excluded by co-staining with the recycle endosome marker Rab11a. 
 
4.3.3 MCPyV truncated LT contributes to the paranuclear retention of c-KIT 
by its interaction with Vam6p 
The c-KIT paranuclear dot-like staining pattern is associated with MCPyV+ MCC, we 
therefore speculated that viral T-antigens could contribute to the intracellular retention of c-
KIT. Indeed, we observed that knockdown of LT and sT could lead to cytoplasmic re-
distribution of c-KIT. Notably, silencing of LT and sT decreased stability of c-KIT protein as 
compared to silencing of sT only or vector control. Additionally, we observed paranuclear 
aggregation of c-KIT only in cells transfected with the truncated LT (LT339) expression. 
Furthermore, the truncated LT also increased c-KIT protein level. As aforementioned, the 
truncated LT interacts with Vam6p to disrupt lysosome clustering (Liu et al., 2011), we 
therefore speculated that the Vam6p-interaction might be the explanation for c-KIT 
stabilization. We constructed the LT339W209A mutant, harboring the Vam6p binding site 
mutation, which disrupted its binding with Vam6p, as demonstrated by co-IP. The c-KIT 
protein stabilization and paranuclear aggregation of LT339 was abolished in the LT339W209A 
mutant. These results indicate that the MCPyV truncated LT promotes paranuclear retention 
and stabilization of c-KIT via Vam6p interaction. 
 
4.3.4 c-KIT binds to BECN1 that enhances BECN1-BCL2 interaction in 
MCPyV+ MCC 
Subsequently, we explored the functional role of c-KIT. Since we previously showed 
autophagy suppression in MCPyV+ MCC (Paper II) and another type of RTK, epithelial 
growth factor receptor (EGFR), has been shown to interact with BECN1 for autophagy 




modulating autophagy in MCPyV+ MCC. Indeed, we demonstrated the interaction between 
c-KIT and BECN1 by co-localization and co-IP. Using a series of deletion mutants of 
BECN1, we showed that c-KIT binds to evolutionarily conserved domain (ECD) of BECN1, 
which is also known to interact with VPS34 for induction of autophagy. We further revealed 
that c-KIT bound to BECN1 that enhanced its interaction with BCL2 and depletion of VPS34 
interaction in MCPyV+ MCC cell lines. Additionally, the same results were obtained in the 
cells transfected with LT339, in which the effect was abolished in the LT339W209 mutant. 
Together, these results demonstrate that MCPyV LT oncoprotein promotes c-KIT and 
BECN1 interaction that enhances BECN1-BCL2 interaction. 
 
4.3.5 Silencing of c-KIT induces autophagy and apoptosis in MCPyV+ MCC 
cells 
To address the functional role of c-KIT, we silenced c-KIT in MCPyV+ WaGa cells and 
observed increased autophagy and apoptosis. However, the increased autophagy was 
observed as early as 24 h, while the stimulation of apoptosis was more obvious at 48 h, 
indicating that the autophagy induction is not the consequence of cell death. We also noted 
that c-KIT silencing did not affect activation of the PI3K-AKT-mTOR signaling, suggesting 
that the activation of autophagy is independent of the signaling.  
To assess the role of BECN1-BCL2 interaction, we treated MCPyV+ cells with ABT-
737, a BH3 mimetic which competes with BCL2 to bind to BECN1 (Maiuri et al., 2007). The 
treatment increased apoptosis in a dosage-dependent manner, which could be partially 
rescued by autophagy inhibitor baf. A1. 
 
4.3.6 MCPyV LT is degraded by autophagy 
We noted down-regulation of LT level upon silencing of c-KIT, in which autophagy inhibitor 
baf. A1 could restore LT expression in c-KIT knocked down cells. This observation 
suggested that LT is degraded by autophagy. To strengthen this observation, we investigated 
the effect of autophagy modulation and proteasome inhibition using chemical approach on 
LT expression in WaGa cells. The results showed that LT was significantly downregulated 
upon autophagy stimulation, but restored upon autophagy inhibition. Moreover, silencing of 
the ATG7 autophagy gene led to LT stabilization. Together, out data support that MCPyV LT 
is degraded by autophagy. 
 
c-KIT overexpression and no detectable activating mutation has been described in MCC 
(Rodig et al., 2012; Swick et al., 2013; Waltari et al., 2011). However, the functional role of 
c-KIT and its correlation with MCPyV status was unknown. In concordance with previous 




expression of c-KIT and SCF has been reported in MCC tumor samples, and SCF-stimulated 
c-KIT is necessary for MCC cell growth in vitro (Kartha and Sundram, 2008; Krasagakis et 
al., 2011; Krasagakis et al., 2009). Together, these findings suggest that c-KIT is activated by 
its ligand.  
One of the highlight points in this study is the observation of paranuclear dot-like 
aggregation of c-KIT in MCPyV+ MCC. Here we identify a mechanism by which MCPyV 
LT induces c-KIT retention via its Vam6p interaction. Given that the LT-Vam6p promotes 
lysosome disruption in MCC (Liu et al., 2011), it is tempting to speculate that MCPyV LT 
affects general lysosomal degradation, and c-KIT is one of them.  
Activation of c-KIT regulates PI3K-AKT-mTOR pathway (Masson and Ronnstrand, 
2009), and mTORC1 complex is involved as a negative regulator for autophagy (Schmelzle 
and Hall, 2000). However, we show that the c-KIT mediated autophagy suppression is 
independent of the PI3K-AKT-mTOR pathway. On the other hand, we showed that c-KIT 
directly interacts with BECN1.  
BECN1 performs a central role for autophagy regulation. It associates with multiples 
cofactors (e.g. Atg14L, UVRAG, Rubicon, Ambra1) to dynamically regulate the BECN1-
Vps34-Vps15 core-complex initiating autophagy flux (Kang et al., 2011). Besides, the BCL2, 
BCL-XL and other BCL2 family proteins could bind to the BH3 domain of BECN1 
(Oberstein et al., 2007). This can lead to suppression or induction of autophagy, as well as a 
multiple crosstalk with apoptosis (Erlich et al., 2007; Kang et al., 2011; Maiuri et al., 2007).  
In concordance with the mechanisms of autophagy suppression by EGFR in lung cancer 
(Wei et al., 2013), Mst1 in cardiac stress and Her2 in breast cancer (Maejima et al., 2013; 
Vega-Rubin-de-Celis et al., 2018), we identify c-KIT as a new BECN1 interacting partner for 
autophagy regulation. Similar to the EGFR-BECN1 mediated autophagy suppression, c-KIT 
binds to the BECN1 on its ECD domain. It is possible that c-KIT might modify the 
phosphorylation sites on BECN1 to alter the BECN1 dimerization for BCL2 binding. 
Therefore, BH3 mimetics (e.g. ABT-737, ABT-263) that can competitively bind to BECN1 
or drugs targeting BECN1 core complex components, such as VPS34 inhibitor SB02024 
(Dyczynski et al., 2018; Maiuri et al., 2007; Noman et al., 2020) can be therapeutic options 
for MCC. In conclusion, this study reveals a mechanism for autophagy regulation via c-KIT-





4.4 MERKEL CELL POLYOMAVIRUS ONCOPROTEIN PROMOTES BAG3-
MEDIATED AGGRESOME FORMATION (PAPER IV) 
Cytokeratin 20 (CK20), the typical diagnostic marker for MCC, is often reported as 
paranuclear dot-like staining pattern in MCC (Alvarez-Gago et al., 1996; Jensen et al., 2000; 
Kervarrec et al., 2019; Leech et al., 2001; Su et al., 2002b; Tanaka et al., 2004). However, the 
identity of this cytokeratin dot-like structure and its function in MCC are uncharacterized. 
Here, we sought to characterize this cytokeratin dot and its relationship to MCPyV T-
antigens. 
 
4.4.1 Paranuclear dot cytokeratin staining is more common in MCPyV+ MCC 
To determine whether the CK20 dot is associated with MCPyV status in MCC, we first 
performed IHC staining of CK20 and another pan-cytokeratin maker MNF116 in three 
MCPyV- and three MCPyV+ MCC cell lines. All three MCPyV+ MCC cell lines harbored 
the paranuclear dot-like staining of CK20 and MNF116, while the cytoplasmic/membranous-
staining pattern was found in all three MCPyV- MCC cell lines. The results were concordant 
with the immunofluorescence staining of MCPyV LT and CK20 in clinical samples, in which 
CK20 dot was more frequently found in MCPyV+ MCC tumors compared to the MCPyV- 
cases. Using the transmission electron microscopy, we also observed a whorl-like 
intermediate filament structure located adjacent to nucleus and surrounded by multiple 
mitochondria, which highly resembles the intermediate filament cage of aggresome (Johnston 
et al., 1998). 
 
4.4.2 The cytokeratin paranuclear dot-like structure is an aggresome and its 
formation is BAG3-dependent 
To demonstrate whether the cytokeratin paranuclear dot could be an aggresome, we applied 
immunofluorescence assays for co-localization analyses between pan-cytokeratin MNF116 
and aggresome markers. The results showed strong co-localization between the cytokeratin 
dot and BAG3, Ub(K48) and γ-tubulin, but not with HDAC6. Aggresome formation requires 
the dynein motor complex for transporting the misfolded proteins along the microtubule track 
towards MTOC, which is marked with γ-tubulin (Olzmann et al., 2008). Upon 
depolymerization of the microtubule, the MNF116 paranuclear aggregation was disrupted. 
Additionally, overexpression of the dynamitin, which disturbs the dynactin complex (Shrum 
et al., 2009), also reduced number of cells with MNF116 aggregation. Together, our data 
support that the cytokeratin paranuclear dot-like structure in MCPyV+ MCC is aggresome.  
Two mechanisms are known to contribute to aggresome formation, i.e. chaperone-BAG3 
pathway or Ub-HDAC6 pathway (Gamerdinger et al., 2011; Kawaguchi et al., 2003). To 
further characterize which one is involved in the MCPyV-associated aggresome formation, 




formation. We observed that the aggresome was disrupted upon BAG3 silencing, while no 
effect was observed in the HDAC6 silencing group. These results indicate that the 
paranuclear cytokeratin dot-like structure in MCPyV+ MCC is a BAG3-dependent 
aggresome. 
 
4.4.3 The Vam6p binding site of MCPyV LT oncoprotein is required for 
aggresome formation in MCPyV+ MCC 
Since the aggresome structure is associated with MCPyV+ MCC, we wanted to determine if 
the MCPyV T-antigens were involved in aggresome formation. We showed that only 
silencing of both LT and sT, but not sT only, led to aggresome clearance in WaGa cells. On 
the other hand, only ectopic expression of truncated LT LT339 recapitulated the aggresome 
formation in MCPyV- cell line.  
To explore whether the LT-Vam6p binding is involved in the aggresome formation, we 
transfected LT339 or LT339W209A, Vam6p binding defective mutant, into the HEK-293 cells 
and evaluated the effect on aggresome formation. Indeed, the aggresome formation was 
markedly decreased in the LT339W209A mutant compared to both LT339 and vector control. 
These results indicate that the LT-Vam6p interaction is essential for aggresome formation in 
MCPyV+ MCC. 
 
Herein, we revealed that the CK20 paranuclear dot is associated with MCPyV+ MCC, 
and this structure is BAG3-mediated aggresome, which is partly contributed by MCPyV 
truncated LT through its Vam6p interaction. CK20 expression pattern is distinct in both 
Merkel cell and MCC, in which diffuse cytoplasmic in Merkel cells and paranuclear dot in 
MCCs (Moll et al., 1992). Cytokeratin (CK) proteins constitute two major subgroups of 
intermediate filaments, which undertake cytoskeletal formation and mechanical basis for 
epithelial cells (Chang and Goldman, 2004). Given some cytokeratins are tissue-specific and 
their expressions are normally preserved during tumorigenesis, CKs are commonly used for 
diagnosis in many different cancer types, such as breast, colorectal and gastric (Braun et al., 
2000; Maehara et al., 1996; Wong et al., 2009). As aforementioned, CK20 expression is used 
for diagnosis of MCC, regardless of the virus status (Lebbe et al., 2015). Notably, despite the 
CK20 dot is preferentially found in MCPyV+ MCC, around half of the MCPyV- MCC 
tumors (46/96) had CK20 dot, which hints the involvement of other mechanism for CK20 
paranuclear aggregation beyond the viral oncoprotein. Nevertheless, the MCPyV truncated 
LT is partly responsible for aggresome formation via Vam6p.  
Vam6p (also known as VPS39) is the key subunit of the Homotypic fusion and protein 
sorting (HOPS) complex, which is required for late endosome and lysosome fusion and 
protein aggregates clearance (Babazadeh et al., 2019; Pols et al., 2013). In MCC, Vam6p is 




it is tempting to speculate that the aggresome formation in MCPyV+ MCC is a consequence 
of protein-degradation failure induced by LT-Vam6p interaction. Besides Vam6p, we also 
showed that this aggresome formation is dependent on BAG3 co-chaperone. BAG3 mediates 
the transportation of HSP70-bound targets via dynein-motor along the microtubule 
(Gamerdinger et al., 2011). The impairment of proteasome degradation can lead to BAG3 up-
expression, which sequesters proteasomal clients into aggresome for autophagic degradation 
(Minoia et al., 2014). However, we did not observe any effect on BAG3 level upon 
modulation of MCPyV T-antigens or the interaction between BAG3 and LT by co-IP (data 
not shown). Whether LT affects BAG3 subcellular localization and/or its associated partners 
have yet to be investigated.  
Although aggresome is a cellular defense response towards toxic misfolded proteins, this 
structure resembles viral factory that has been observed in other DNA viruses, such as 
adenovirus, herpes virus and African swine fever virus (Heath et al., 2001; Liu et al., 2005; 
Nozawa et al., 2004). Given the MCPyV in MCC tumors loses its replication ability due to 
the truncated mutations of LT eliminating the helicase domain required for viral replication 
(Shuda et al., 2008), it is unlikely that aggresome in MCPyV+ MCC serves as viral 
replication platform. Banerjee and colleagues reported that Influenza A could harness the host 
HDAC6-dynein aggresome system to assist its infection (Banerjee et al., 2014). Therefore, 
the aggresome formation may happen in the early stage of MCC or during MCPyV viral 
infection. On the other hand, aggresome could act as cytoprotective compensatory response 
against the cytotoxicity of accumulated misfolded proteins upon proteasome impairment 
(Bjorkoy et al., 2005; Takahashi et al., 2018). Our preliminary data showed that disrupting 
aggresome formation by dynamitin overexpression increases cytotoxicity in WaGa cells (data 
not shown), suggesting cytoprotective role for aggresome in MCPyV+ MCC. 
In conclusion, we identify a BAG3-mediated aggresome in MCPyV+ MCC, in which the 
Vam6p binding site of the LT oncoprotein is required for promoting aggresome formation, 






Protein degradation system is an essential networking that transfers the misfolded proteins 
and damaged organelles into elementary molecules for cellular homeostasis maintenance and 
recycling energy supply. Various factors could interfere with degradation system to regulate 
tumor development with diverse dimensions. This thesis partly contributed to the molecular 
understanding of miRNAs and viral oncoproteins involved in cellular degradation pathways. 
The general finding are summarized as the following: 
 
• miRNAs can regulate key genes involved in cellular degradation pathways, such as 
miR-223-3p regulation of FBXW7 E3 ligase in TGCT and miR-375, miR-30a-3p, 
miR-30a-5p regulation of BECN1, SQSTM1, ATG7 in MCC (Papers I and II). 
 
• MCPyV T-antigens suppress autophagy through miRNAs (i.e. miR-375, miR-30a-3p, 
miR-30a-5p) and c-KIT mediated BECN1-BCL2 interaction in MCC (Papers II and 
III). 
 
• Autophagy induces MCPyV LT degradation and apoptosis in MCC (Papers II and 
III). 
 
• c-KIT directly binds to the ECD of BECN1 that diminishes the BECN1-VPS34 
interaction, while enhancing the BECN1-BCL2 interaction for autophagy suppression 
(Paper III). 
 
• The Vam6p binding site of MCPyV truncated LT is required for paranuclear retention 







6 FUTURE PERSPECTIVE 
As described in the introduction section and several studies in this thesis, it is not surprised 
that protein degradation system interplays with enormous aspects in cancer development and 
is regulated by multiple factors. One of such factors is miRNA. We show that miR-223-3p 
regulates the E3 ligase FBXW7 in TGCT (Paper I), while miR-375, miR-30a-3p and miR-
30a-5p target multiple autophagy factors in MCC (Paper II). In Paper I, although we 
demonstrated that miR-223-3p regulates cell growth and apoptosis through FBXW7, it is still 
unclear whether miR-223-3p overexpression in TGCT increases protein stability of specific 
FBXW7 substrates that are required for TGCT development. Identification of the 
downstream targets of the miR-223-3p-FBXW7 regulation would be relevant to improve our 
understanding of this disease. In Paper II, we demonstrate that MCPyV T-antigens can 
induce miRNA expressions through the DnaJ domain of the viral T-antigens. Several 
outstanding questions have been raised from this finding. For example, how does the DnaJ 
domain of the viral T-antigens contribute to miRNA regulation? How does this regulation 
contribute to selective processing of specific miRNAs?  
Another factor is the viral oncoprotein. In Papers III and IV, we found that the Vam6p 
binding site of MCPyV truncated LT can promote intracellular retention of c-KIT and 
aggresome formation. In Paper III, the functional consequences of the c-KIT-mediated 
BECN1 complex dynamics of autophagy suppression have yet to be determined in MCPyV+ 
MCC. Furthermore, c-KIT is a kinase receptor, it is unclear whether the kinase function is 
required for the BECN1 interaction. Further investigations are needed to determine the 
BECN1 phosphorylation and dimerization status and other BECN1 interactomes. 
Additionally, the importance of the c-KIT-BECN1-BCL2 interaction in MCC tumorigenesis 
has yet to be determined and the effect of BH3 mimetics on MCC xenografts. The findings in 
Paper III also raise a question whether c-KIT-BECN1 interaction happens in other tumor 
types. Indeed, our preliminary data also showed that c-KIT directly interacts with BECN1 in 
GIST (unpublished data).  
In Paper IV, functional consequences of the aggresome formation have yet to be 
investigated in MCC. Besides, the aggresome in MCC could also be the treatment target. 
Similar strategy has been used in pancreatic cancer cells, in which they inhibit HDAC6 to 
disrupt the bortezomib-induced aggresome formation that sensitizes the aggresome-positive 
cell to apoptosis via ER stress (Nawrocki et al., 2006). Further understanding of aggresome 
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